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PURPOSE: To assess adherence and compliance of individuals diagnosed with 
Schizophrenia Spectrum Disorders (SSDs) to a 6-month, progressive walking program. 
Changes in physical and psychological outcomes were also evaluated. METHODS: Subjects 
attended group-based walking sessions biweekly at local mental health clinics. RESULTS: 
Subjects attended 34% of group walks and wore their Fitbits 51% of the prescribed time. 
Compliance to individualized prescribed heart rate training ranges for home-based and 
group-based active minutes were low (0.6, and 4.9% respectively). However, subjects overall 
active minutes throughout the study surpassed the prescribed dosage, achieving 179% 
prescribed active minutes, which may help explain significant improvements in the 6-minute 
walk test distances (pre 377 ± 112m, post 466 ± 128 intervention, p < 0.001, ES = 0.142). 
CONCLUSION: Despite low adherence to group walking and compliance to HR training 
zones, significant improvements in cardiorespiratory fitness were observed, likely from 
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CHAPTER ONE: INTRODUCTION 
Background 
 Schizophrenia spectrum disorders (SSDs) are severe mental illnesses (SMI) in which 
individuals have a decreased life expectancy of up to twenty-five years when compared to the 
general population (Wildgust & Beary, 2010). However, the causes behind these mortalities 
are not unlike the causes of death as seen in the general population (Brown, Barraclough & 
Inskip, 2000), with the leading cause being cardiovascular disease (CVD) (Hjorthøj, Stürup, 
McGrath & Nordentoft, 2017). This may be due to the fact that individuals with SSDs are 
more susceptible to risk factors leading to CVD, including increased physical inactivity 
(Blair, 2009), as a result of their mental illness. Lack of physical activity (PA) is highly 
associated with significantly decreased health in both the general population and populations 
with SMIs, increasing overall risk for development of severe health conditions (Leitzmann et 
al, 2007; Vancampfort et al, 2017). In the field of exercise science, there is sufficient 
research on exercise interventions eliciting improvements in the quality of health of the 
general population from increased levels of physical activity (Kodama et al, 2009). There is 
growing evidence that exercise would yield similar results for individuals with SSDs, 
however an appropriate and specific exercise prescription for this population is lacking in the 
field, along with detailed reports of adherence and compliance.  
To better demonstrate the negative health impact that these SMIs have on individuals, 
SSDs accounts for an economic burden of more than $60 billion per year in the United States
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alone (Chong et al., 2016). This includes the medical costs associated with SSDs as well as 
the overall productivity loss from both individuals with SSDs and their family members and 
caretakers (Chong et al, 2016; Doran & Kinchin, 2019). SSDs cause such an economic 
impact due to the fact that the disease onset occurs fairly early in an individual’s life and 
often results in persistent symptoms that must be managed throughout a person’s lifetime 
(Chong et al, 2016).  
Both the symptoms and side effects of these disorders and treatment for these 
disorders have led this clinical population to become extremely sedentary for a multitude of 
reasons. These may include lack of energy and motivation, shame and embarrassment to 
leave the home due to stigma surrounding mental illness, lack of available infrastructure to 
participate in PA (Connolly & Kelly, 2005), and lack of time and social support, poor 
weather, disturbances to current routines and dislike of exercise (Dunn, et al, 1999). Overall, 
individuals with SSDs regularly spend up to 12.5 waking hours/day sedentary, compared to 
the general population regularly spending an average of about 9 waking hours/day sedentary 
(Stubbs, Williams, Gaughran & Craig, 2016), with motivation being the most reported cause 
of lack of engagement in activity (Firth et al, 2016). Lack of motivation may be addressed 
through a support-group-like session held to help individuals address barriers and goals 
throughout an exercise intervention.  
There is a well-documented relationship existing between sedentary behavior, poor 
cardiorespiratory fitness (CRF) and increased risk of developing CVD in the general 
population (Kodama et al, 2009). However, physical activity and exercise have known 
protective factors that have been shown to help reduce the likelihood and severity of CVD in 




associated with improved CRF (Kodama et al, 2009). There is growing evidence to support 
that individuals with SMI, including SSDs, would have a similar physiological response to 
exercise as the general population. Specifically, studies have shown that exercise 
interventions within this population have the potential to elicit improvements in weight, body 
mass index (BMI), and cardiorespiratory fitness (CRF) (Bartels et al, 2013; Browne, Penn, 
Battaglini, & Ludwig, 2016; Daumit et al, 2013). Therefore, implementing an intervention 
with the goal of improving physical activity participation would prove beneficial to this 
inactive population. 
However, it is first important to evaluate adherence and compliance of individuals 
with SSDs to various exercise intervention While there is growing literature on exercise and 
individuals with SMI, there remains a significant gap in the research in this field. What 
remains unknown is how well individuals with SSDs adhere to a walking group based 
intervention and how well they comply with an intensity prescription based on HR. It is 
important to determine the feasibility of an intervention that focuses on a prescribed HR 
range based on progressive intensity in order to determine the practicality of implementing 
an exercise program in treatment plans for individuals that have been diagnosed with SSDs. 
Monitoring HR during aerobic activity through the utilization of a physical activity tracker is 
an important step to qualify intensity in an objective fashion (Freedson & Miller, 2015). 
Through increasing HR during activity, other health related outcomes, such as resting heart 
rate, resting blood pressure, weight, and waist and hip circumferences, each of which that are 
indicators of CVD will likely improve with increase physical activity in the form of walking 





Statement of Purpose 
 The purpose of this study was to determine the adherence and compliance of 
individuals with SSDs to a 6-month group-based walking intervention held at local mental 
health clinics to help assess the feasibility of implementing physical activity programs in 
routine treatment for this clinical population. The intervention included progressive (distance 
and intensity) group walks, prescribed home-based walks, use of a Fitbit for monitoring of 
walking distance and intensity. Walking is a well tolerated and effective mode of exercise for 
individuals dianogsed with SSDs while Fitbits are user-friendly and cost-effective technology 
to assess physical activity through motion detection. The secondary purpose was to evaluate 
physical functional and health-related outcomes. The tertiary purpose was to evaluate 
subjects’ motivation towards physical activity, due to the fact that motivation is a highly 
reported barrier to participation in physical activity in this population. 
 
Research Questions 
RQ1: Will individuals diagnosed with SSDs adhere and comply to a 6-month walking 
intervention protocol?  
RQ2: Will improvements in functional and health-related outcomes, including 
6MWT, resting heart rate, resting blood pressure, mean arterial pressure, hip 
circumference, waist circumference, waist to hip ratio, body mass index and weight, 




RQ3: Will the motivation of individuals with SSDs towards physical activity and 
exercise change over the course of a 6-month walking intervention?  
 
Hypothesis 
H1: Subjects participating in a 6-month walking intervention will have adherence and 
compliance rates of 50%.   
H2: Assuming subjects will adhere to at least 50% of the training prescription, 
functional and health-related outcomes including 6MWT, resting heart rate, resting 
blood pressure, mean arterial pressure, hip circumference, waist circumference, waist 
to hip ratio, body mass index and weight will improve significantly in individuals 
with SSDs over a 6-month exercise intervention. It is believed that 50% of the 
prescribed amount of activity is a reasonable amount to elicit improvements in these 
measures based on adherence and compliance rates reported in the literature. 
H3: Motivation towards physical activity and exercise will improve over the course of 
a 6-month exercise intervention. 
 
Definition of Terms 
Adherence: For the purpose of this study, adherence is defined in terms of both group 
participation adherence and device (Fitbit) adherence. Participation adherence is defined as 




prescribed. Device adherence is defined as the percentage of days the subject had worn their 
Fitbit device compared to the total number of days they were in possession of the device. 
Compliance: Compliance is defined in terms of subjects’ active heart rate during group walks 
compared to the prescribed heart rate range, subjects’ active heart rate during home-based 
walks compared to the prescribed heart rate range, and subjects’ total number of active 
minutes compared to total number of active minutes prescribed, without taking heart rate into 
consideration.  
Active Minutes: Active minutes are defined as periods of time greater than fifteen minutes,  
during which an individual is participating in movement that is sustained at greater than 
resting levels, regardless of heart rate at the time of activity. Fifteen minutes is the amount of 
time which is the threshold for bouts of activity to be automatically recorded from the Fitbit 
tracker.  
Physical Activity and Exercise: For the purposes of this thesis, the terms physical activity 
and exercise will be used interchangeably, indicating any increase in energy expenditure 
above resting levels. 
Sedentary and Physically Inactive: For the purposes of this thesis, the terms sedentary and 
physically inactivity will be used interchangeably, indicating that an individual or group of 
individuals are not meeting current guidelines for the recommended amount of physical 







1. All subjects answered questionnaires truthfully. 
2. All subjects adhered to keeping their Fitbit device charged and worn during all 
waking hours. 
3. Subjects did not share their Fitbit with anyone else for the duration of their 
participation in the study. 
  
Limitations 
1. Time of day of testing may have varied between subjects due to scheduling conflicts 
including work shifts, medical appointments, family matters, etc.  
2.  Fitbit devices used were determined to be older technology and may create 
inaccurate or variable data in relation to resting and active heart rate values and 
minutes spent active. 
3.  Training and reassessment occurred during peak summer heat, which may have 
influenced the results of post-intervention assessments. 








2. All subjects were prescribed walking intensities based on their personal resting heart 
rates using the heart rate reserve method that were updated with each new intensity 
range as the intervention progressed. 
  
Significance of the Study 
 Exercise physiology literature is limited in its research involving the examination of 
physical activity interventions in individuals diagnosed with SMIs, such as SSDs. There is 
currently some evidence to support that by increasing physical activity, individuals with 
SSDs will see improvements in aerobic capacity, thus decreasing risk factors and 
comorbidities that oftentimes lead to premature mortality  (Firth, Cotter, Elliot, French & 
Yung, 2015; Rosenbaum, Tiedemann, Sherrington, Curtis & Ward, 2014). This study is an 
important step that will help provide a deeper understanding of the feasibility and efficacy of 
increasing physical activity and improving CRF in individuals with SSDs. This may be 
accomplished by utilizing an intervention that may offset some of the barriers for 
engagement in regular physical activity for these individuals, who often time face significant 
barriers to participating in physical activity, including lack of support and motivation. It is 
important to determine the feasibility of prescribing intensity based on HR so that 
interventions in the future may use this method to determine appropriate exercise 
prescriptions for individuals with SSDs.  
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CHAPTER TWO: LITERATURE REVIEW 
Overview 
 For the purpose of organization, this review is subcategorized into three sections. The 
first section of this literature review is a comprehensive assessment of the definition and 
diagnosis of SSDs, types of signs and symptoms associated with SSDs, as well as 
epidemiology of the illness. The second section outlines the consequences of living with 
SSDs, as well as the treatments prescribed to individuals with SSDs, along with the side 
effects of treatments. The third and final section is a review of the benefits of exercise in both 
healthy individuals, as well as any research that has been done involving individuals with 
SSDs and exercise interventions. The third section also discusses the known barriers to 
physical activity in this clinical population. 
 
Section 1.1 Epidemiology 
SSDs affects over 20 million people worldwide, which is about one percent of the 
global population (Spaulding, Silverstein, & Menditto, 2017). Overall, every 1 in 150 
individuals globally will be diagnosed with a form of psychotic disorder at some point in 
their lifetime (Moreno-Ku ̈stner, Mart ́ın, & Pastor, 2018). SSDs have a point prevalence of 
approximately 4.6 per 1,000, a period prevalence of 3.3 per 1,000, a lifetime prevalence of 
4.0 per 1,000 and a lifetime morbid risk of 7.2 per 1,000 and a median annual incidence of
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onset of 15 in 100,000 (Kruse & Schulz, 2016). Although incidence rates are relatively 
consistent worldwide, they are, overall, seen to be higher in older studies performed, most 
likely due to different diagnostic criteria (Epping & Black, 2016; Kruse & Schulz, 2016). 
Differing diagnostic approaches and methodology causes reports of SSDs to vary, however, 
overall prevalence reports typically range from 4 to 7 per 1,000 persons consistently (Saha, 
Chant, Welham, & McGrath, 2005). 
SSDs onset are typical during late adolescence or early adulthood, with the peak age 
being reported between 15 and 24 years old. Normally, men will experience SSDs onset 
earlier and more often than women (Epping & Black, 2016). However, prevalence of SSDs 
does not vary between sexes (Saha, Chant, Welham, & McGrath, 2005). 
SSDs are said to be among the most, if not the most, severe and debilitating mental 
illnesses and rank amongst the top worldwide reasons for lifelong disability (Kruse & Schulz, 
2016). SSDs diagnoses are greatly related to disability, due to their incurable nature and 
difficultly managed symptoms. Of all disabled persons in the United States, ten percent are 
diagnosed on the schizophrenia spectrum (Spaulding, Silverstein, & Menditto, 2017). 
Schizophrenia disorders are within the top 15 causes of disability worldwide (Moreno-
Ku ̈stner, Mart ́ın, & Pastor, 2018). 
 
Section 1.2 SSDs: Signs, Symptoms and Diagnoses 
One of the most important features of an SSD diagnosis is that the person experiences 
at least two out of the following five symptoms: hallucinations, delusions, disorganized 




presence of both positive and negative symptoms – positive symptoms being those not 
present in the general population and negative symptoms being those present in the general 
population but not those with mental illness – must be continuous for at least six months in 
order for an appropriate diagnosis to be made (Spaulding, Silverstein, & Menditto, 2017). 
Negative symptoms typically occur first, and may first present up to five years prior to the 
first psychotic episode (Epping & Black, 2016). These symptoms are also more difficult to 
treat pharmacologically. Disorganized thought and behavior are also more difficult to treat in 
general, being that disorganization is the “fragmentation and breakdown of psychological 
functions needed to organize behavior for specific purposes” (Spaulding, Silverstein, & 
Menditto, 2017). 
Along with the more trademark symptoms of SSDs, such as hallucinations and 
delusions, it is important to note that some signs and symptoms may be present prior to the 
onset of SSDs, a time that is known as the prodromal period. Prodromal symptoms include 
delayed or difficulties in social functioning (Epping & Black, 2016; Spaulding, Silverstein, & 
Menditto, 2017) along with mild delays in cognition and development during childhood 
(Epping & Black, 2016). Other prodromal symptoms include social isolation and/or 
withdrawal, disorganized thoughts and behavior, negative symptoms and functional 
deterioration (Fu & Cadenhead, 2005). Other information used to diagnosis an individual 
with SSDs includes minor anomalies in the person’s physical appearance, including in the 
face, head or extremities (Epping & Black, 2016). About 75% of all persons with SSDs 
experience a prodromal phase, with the subthreshold of psychotic symptoms reported at 
around one year preceding first psychotic episode (George, et al, 2017). Individuals that are 




primarily anxiety, are more likely to develop psychosis (Yung, Phillips, Yuen, & McGurry, 
2004).  
 
Section 1.3 Risk Factors of SSDs 
There are several factors that may predispose individuals to SSDs including family 
history, genetics, location, ethnicity, gender, socioeconomic status, culture, exposure to 
infection, season of birth, parental age and history of drug use. These risk factors are best 
described through the stress-vulnerability model, which is one of the best methods that the 
field uses to understand SSDs risk and development. This model describes what causes 
psychiatric disorders, why some individuals develop them but others do not and what affects 
the cause of these disorders. In this model, vulnerability describes an individual’s biological 
predisposition to develop a mental health disorder, such as SSDs, due to genetics, prenatal 
nutrition and stress, birth complications, early life experiences and medications. An 
individual’s biological vulnerability may be influenced further by alcohol and drug use. 
Individuals that are susceptible to developing a mental illness are also more likely to be 
involved in drug and alcohol use. The second part of this model, stress, describes the 
challenges an individual faces in life. Stress can be affected by an individual’s coping skills, 
social support and participation in meaningful activities. The amount of stress an individual 
is exposed to can have an affect on biological vulnerability to eventually lead to the 
development of SSDs. Each of the previously mentioned variables can dictate the severity of 
symptoms, the potential for relapses as well as hospitalization. This model also makes it clear 




the more severe their symptoms are likely to be. Individuals can make modifications to 
various lifestyle factors affecting their coping skills, social support, meaningful activities and 
substance use, including medications, that may help reduce the severity of symptoms (The 
Stress-Vulnerability Model of Co-occurring Disorders, 2008).  
There have recently been further discoveries to support the concept that genetics play 
a significant role in an individual’s risk for developing psychosis.  An individuals’ genetic 
make up plays an important role in overall health and risk of co-morbid disease development. 
Genetics account for up to 80% of an individual’s predisposition for developing a condition 
such as SSDs (Girdler, Confino, & Woesner, 2019). Therefore, if a family member is 
diagnosed with psychosis it is likely that another individual will as well. For example, if one 
identical twin is diagnosed with an SSD, there is a 40% chance that the other twin will also 
be diagnosed at some point in his or her lifetime. If an individual’s fraternal twin is 
diagnosed with an SSD, there is a 17% that they will also be diagnosed with this condition. 
An individual has a 13% chance of developing psychosis if one of his or her parents has an 
SSD, and a 9% chance if one of his or her siblings is diagnosed with an SSD (Girdler, 
Confino, & Woesner, 2019). Beyond familial risk factors, scientists have recently discovered 
the potential allele, C4 that is responsible for the onset of psychosis. Sekar et al. (2016) made 
the claim that the allele, C4, which is expressed by neurons, localized to dendrites, axons, 
and synapses, and secreted, promotes synapse elimination during the developmentally timed 
maturation of a neuronal circuit. The late phase of cortical maturation corresponds to the 
period of time during which psychosis, along with other symptoms of SSDs, become 
clinically obvious and individuals begin to suffer from functional cognitive decline. It is 




pruning during late adolescence and early adulthood are the underlying cause to SSDs 
(Sekar, et al, 2016).  
While many risk factors are explained through the stress-vulnerability model and 
genetic-based research, there are several others that appear to influence an individual’s risk 
of developing SSDs. Incidences of SSDs are 2 to 4 times greater in urban versus nonurban 
areas (Epping & Black, 2016; Kruse and Schulz, 2016). Also, individuals that migrate from 
one part of the world to another other than their country of origin and destination are at 
increased risk of SSDs (Epping & Black, 2016). Furthermore, an individual is at higher risk 
if in a developing country rather than a developed country (Kruse & Schulz, 2016). Aside 
from location, culture and ethnicity may also put an individual at greater risk for developing 
SSDs. Individuals that identify as African American, among other minorities, present with 
greater instance of SSDs diagnoses. This may be due to health disparities or bias in over-
diagnoses amongst these populations of people (Epping & Black, 2016). Individuals 
diagnosed with SSDs are also more likely to be from the lowest socioeconomic class (Epping 
& Black, 2016). 
Another risk factor for exposure to development of SSDs is history of drug use. With 
the exclusion of alcohol, persons who use drugs, specifically cocaine and other stimulants, 
have increased risk and earlier age of onset for SSDs than individuals with no history of drug 
use (Epping & Black, 2016). There is also much supporting evidence that marijuana use 
increases the likelihood of developing psychosis, even when controlling for the use of other 
substances (Kelley et al, 2017) and that marijuana use during adolescence increases risk of 
the development of psychosis (Evins, Green, Kane, & Murray, 2012). Further, DiForte et al. 




cannabis, compared to 37% of control subjects. This study also found that people diagnosed 
with psychosis are up to twice as likely to have been using marijuana for at least the past five 
years, and are up to six times as likely to be daily users. There is also evidence that any 
increase in the use of marijuana in the five years preceding the first episode is predicative of 
the onset of psychosis (Kelley, et al, 2017). 
There are several other factors that are less common but still associated with the 
development of SSDs. These include: exposure to infectious diseases, specifically in utero or 
postnatal infections, such as Toxoplasma gondii (Epping & Black, 2016); in utero exposure 
to complications during pregnancy, including diabetes, bleeding, pre-eclampsia and Rh 
incapability; complications during birth, such as uterine atony, emergency Caesarian 
sections, and asphyxia; and finally abnormalities in fetal growth or development, like 
congenital malformations, low birth weight, and smaller head circumference (Eppings & 
Black, 2016); the season during which an individual is born (individuals born during the 
winter months are at higher risk for developing SSDs later in life) (Epping & Black, 2016); 
and finally, the older the parents of a child, the greater risk of developing the SMI, which is a 
risk that increases with each birth the mother experiences, while risk increases for female 
offspring if the father is greater than 50 years old and for male offspring if the father is 
greater than 55 years old (Epping & Black, 2016). While there is a seemingly endless list of 
risk factors and risk of exposures to developing SSDs, the increased risk is still relatively 






Section 2.1 Consequences of Living with SSDs 
Individuals diagnosed with SSDs are faced with unavoidable consequences and 
hardships, physically, mentally and emotionally. The most significant of these effects include 
comorbidities such as obesity and diabetes, decreased life expectancy and increased 
economic and societal costs (Kruse & Schulz, 2016). While one third of individuals 
diagnosed with SSDs have milder symptoms, resulting in better treatment outcomes, only 
one in seven persons with SSDs will exhibit a full recovery after diagnosis (Epping & Black 
2016). Poor outcomes of treatments in the SSDs population are due to both poor adherence 
and poor response to treatments. These factors, along with past and continual substance use, 
cognition deficits and other mental disorders, and difficulties in accessing appropriate and 
adequate treatment all contribute to poor outcomes. The consequences that individuals with 
SSDs face, along with the poor outcome after they are first diagnosed and treatmented, lead 
SSDs to be the overall greatest rates of individual disability (Epping & Black, 2016). 
Individuals diagnosed with SSDs are an extremely vulnerable population in terms of 
physical health due to the fact that they are at high risk for developing comorbidities. 
Increased instances of the development of comorbidities are oftentimes related to insufficient 
self-care and poor lifestyle habits, leading to cases of diabetes, heart disease and cancer 
(Kruse & Schulz, 2016). Overall, SSDs have three times higher mortality rates than the 
general population (Epping & Black, 2016). This is due to a number of reasons, with the 
most prevalent being chronic pulmonary disease, liver diseases, renal disease, AIDS, 
diabetes, ulcer disease, hemiplegia, any form of tumor, and cardiovascular diseases, such as 
peripheral vascular disease, congestive heart failure and myocardial infarction (Epping & 




Natural causes of death are not the only aspect leading to increased overall mortality 
rates. Suicide, along with suicide attempts and self-harming behaviors, are all increased in 
the SSDs populations (Epping & Black, 2016). Risk of suicide in persons with SSDs is up to 
twelve times greater when compared to the general population (Kruse & Schulz, 2016). 
However, even without considering suicide rates in this population, life expectancy remains 
decreased (Kruse & Schulz, 2016). While suicide rates are increased, natural causes of death, 
mainly involving cardiovascular diseases and cancer, occur more frequently and at younger 
ages in individuals with SSDs than the general population. Contributing factors for increased 
rates of natural deaths at younger ages in the SSDs populations include, but are not limited 
to, extremely high rates of smoking, poor self-care and unhealthy lifestyle behaviors. 
Inconsistent medical care is also an additional factor increasing death rates amongst 
individuals with SSDs (Epping & Black, 2016). 
One of the greatest aspects of an individual with an SSD’s life to face deterioration is 
social function. Persons with SSDs typically have decreased social lives as a result of 
symptoms such as anxiety, depression and paranoia. Individuals with SSDs oftentimes find 
themselves isolated from society, leaving little chance of good social health. Overall, 
individuals with SSDs face more difficulties in both developing and maintaining 
relationships or achieving intimacy with other individuals (Epping & Black, 2016). Not only 
are individuals with SSDs less likely to marry, they are also more likely to remain single for 
up to twenty years prior to diagnosis. Increased apathy, decreased interested in socialization, 
a low sex drive, and increased likelihood of chronic hospitalization or institutionalization all 
contribute to persons with SSDs remaining single, leading to overall decreased fertility and 




Furthermore, individuals with SSDs experience overall greater rates of self reported 
loneliness, up to 2.3 times greater than the general population (Eglit, et al, 2018). This is a 
major concern due to the fact that loneliness is a risk factor for heart disease, depression, 
anxiety and Alzheimer’s disease (Hawkley & Cacioppo, 2010). There is also evidence to 
support loneliness as one of the earliest symptoms of neurocognitive disorders, especially 
when associated with aging (Donovan et al, 2016). Loneliness negatively impacts health and 
is associated with negative interpersonal expectations and attributions of others, internalized 
stigma, lower self-efficacy for community life, lower self-esteem, paranoia, depression, 
anxiety, hypertension and abnormal hemoglobin A1c levels (Eglit et al, 2018). Individuals 
with mental health disorders, especially psychosis, are prone to loneliness. Individuals with 
SSDs experience loneliness due to facing stigma, greater clinical challenges, greater levels of 
socio-environmental difficulties including poverty and lower rates of employment and 
marriage, as well as objectively being less integrated into their communities (Eglit, et al, 
2018).  
 One of the greatest barriers that individuals with SSDs face daily is the stigma 
associated with severe mental illnesses. The negative stigma associated with SSDs oftentimes 
results in people hiding symptoms and failing to seek adequate treatment and support 
(Aberholden, Pientka, & Schulz, 2016). Stigma does not only affect treatment however, it 
also negatively impacts individuals with SSD’s social lives, as they are often thought of as 
“crazy,” “dangerous,” “incompetent,” and many other derogatory terms that keep them from 
finding friends and an adequate support system (Aberholden, Pientka, & Schulz, 2016). 
Stigma also adds to an impaired ability to obtain a job, contributing to the fact that only a 




2016). Lack of work, friends, and support contributes to feelings of isolation and may lead to 
individuals “self-stigmatizing” themselves, resulting in these individuals having low self-
esteem and self-worth (Aberholden, Pientka, & Schulz, 2016). The stigma that individuals 
with SSDs face deters them from participating in physical activity and community-based 
activities, which may be something that can be combatted through a group-based intervention 
for individuals with SSDs.  
 
Section 2.2 Current Treatment of SSDs  
There are several different paths of treatment that individuals may choose when it 
comes to managing SSDs, with a range of therapies targeting both biological and 
psychological symptoms (Janicak & Hussain, 2016). It is crucial that the treatment and 
rehabilitation plan selected be specific to the individual and his/her goals (Spaulding, 
Silverstein, & Menditto, 2017). Treatments may be either psychosocial or pharmacological in 
nature. Psychosocial therapies typically include cognitive behavioral therapy (CBT) and 
social skills training, following the Patient Outcomes Research Team (PORT) treatment 
recommendations. Pharmacological treatments typically focus on antipsychotic medications, 
especially clozapine. Treatment plans usually involve a combination of therapies and support 
groups, such as rehabilitation counseling, collaborative psychopharmacotherapy, 
neurocognitive therapy, individual psychotherapy, family therapy and peer support groups, 
self-help groups and community living, in addition to those listed above, as well as 
medications to assist in managing symptoms and other co-occurring mental conditions such 




Cognitive behavioral therapy is a strategy that utilizes a structured psychological 
treatment plan to assist in improving symptoms of mental illnesses (Sensky, et al, 2000). This 
type of therapy is effective in managing and treating both negative and positive symptoms 
through the following techniques: processing and learning to deal with adversity; role 
playing; learning coping strategies and skills, which start externally and then work to become 
internalized (Morrison, 2009). CBT has been proven to successfully treat symptoms that are 
not responsive to antipsychotic medications (Sensky et al, 2000), as well as being an 
effective long-term treatment plan (Morrison, 2009). CBT produces large clinical effects of 
the symptoms of SSDs, but also provides individuals with additional benefits beyond routine 
treatment and supportive therapy methods (Rector & Beck, 2017).  
Social skills training is also one of the most successful treatment methods at 
providing individuals with SSDs behavioral techniques and methods to improve and manage 
their symptoms. Social skills include improving negative symptoms, as well as psychosocial 
functioning (Kurtz & Mueser, 2008). This type of training allows individuals with SSDs to 
participate in learning activities that help them to acquire behavioral techniques to develop 
interpersonal disease management and independent living skills to improve their ability to 
function in the community (Kopelowicz, Liberman, & Zarate, 2006).  
Patient Outcomes Research Team (PORT) reports are guidelines that provide 
recommendations of treatment for individuals with SSDs that are based on empirical 
evidence and are continually updated as new findings are published, with the goal of 
“[increasing] the use of evidence-based treatments in order to optimize outcomes by reducing 
illness symptoms and the disability and burden associated with the illness” (Kreyenbuhl et al, 




with an emphasis on prescribing clozapine, an antipsychotic medication, as well as 
psychosocial therapies, such as skills training and CBT. The PORT guidelines encourage 
providers to not only manage an individual’s symptoms but also focus on the big picture goal 
of enhancing the overall wellbeing of individuals through comprehensive treatment plans.  
 Oftentimes a large part of a person’s rehabilitation strategy involves the individual’s 
family, as noted with family therapy being one of the many treatment options. It is important 
that the family, or individuals closest to the person facing an SSD, be part of the treatment 
plan to help them adhere as best they can to the rehabilitation plan. Family members are also 
healthcare professionals’ best references to note any observations or changes in behavior in 
the indivdual, as it may be difficult for the care team to note everything due to the fact that 
they may not spend a lot of time with the person (Abderholden, Pientka & Schulz, 2016).  
Family also play a crucial role in building plans for emergency situations, such as when an 
individual exhibits extremely aggressive or violent behavior, or exhibit suicidal or self-
harmful behaviors.  
 Medications are a large part of treatment plans for individuals with SSDs to help 
manage symptoms as well as co-occurring disorders. Persons with SSDs oftentimes take 
antipsychotics as well as other psychotropic medications (Stroup et al, 2019). Antipsychotics 
can be broken down into three classes including conventional (typical), atypical and 
dopamine partial agonist. Each of these acts on the dopamine system, however, their effect is 
limited and therefore must be supplemented with adjunctive pharmacy to augment the effects 
of the treatment (Miyamoto, Duncan, Marx, & Lieberman, 2005). While antipsychotics are 
effective at managing the positive symptoms of SSDs, there is little impact on the negative 




2012). Therefore, persons with SSDs must take additional medications, such as 
antidepressants, benzodiazepines and mood-stabilizers to target the symptoms of SSDs not 
affected by the antipsychotics. While adjunctive antidepressants are successful in decreasing 
risk of hospitalization or visits to the emergency room for individuals with SSDs, adjunctive 
benzodiazepines and mood-stabilizers do not elicit such benefits (Stroup et al, 2019).  
 Currently, exercise as part of treatment plans for individuals with SSDs is lacking 
attention. Healthcare providers often prescribe various types of therapies and medications to 
individuals with SSDs, but do not suggest increasing physical activity, as it does not take 
high priority, despite the probable benefits to both the physical and mental health and 
wellbeing of this clinical population. Despite the growing literature to support physical 
activity as part of treatment for individuals with SSDs, there is no clear or standard method 
for clinicans to follow in order to prescribe exercise (Pearsall et al, 2014). There is currently 
a call for greater focus on the physical health of indiviudals with SMIs as part of treatment 
plans (Firth et al, 2019), as exercise has been proven to treat symptoms of SSDs that 
medications have not, such as cognition (Girdler, Confino, & Wosener, 2019). There have 
also been claims to make fitness, specifically cardiorespiratory fitness, a measure of health 
not only in populations with SMIs, but all clinical population (Ross et al, 2016).  
 
Section 2.3 Side Effects of Treatment of SSDs 
 There are many side effects of the treatment of SSDs that often contribute to the 
decreased life expectancy of this population. The most notable side effects from management 




not all antipsychotics cause weight gain, some medications in this class, including clozapine 
and olanzapine cause weight gain significant enough to have serious health implications 
(Connolly & Kelly, 2005). Weight gain is greatest in those taking second-generation 
antipsychotic medications, such as clozapine (Correll, Detraux, De Lepeleire, & DeHert, 
2015). These weight gains often cause changes in body mass index (BMI) class from normal 
weight to overweight or obese. Individuals with SSDs are 2.8-4.4 times more likely to be 
obese compared to the general population (Correll, Detraux, De Lepeleire, & DeHert, 2015). 
Antipsychotics are not only associated with weight gain, but are also known to impair 
glucose metabolism (Connolly & Kelly, 2005), increase cholesterol and triglyceride levels, 
and cause arterial hypertension. Each of these criteria contribute to metabolic syndrome, 
which increases risk of developing diabetes mellitus by five times, and cardiovascular 
conditions by two times over the course of five to ten years (Dayabandara, et al, 2017).  
There are further concerns over the side effects of newer antipsychotics, that also 
cause weight gain, diabetes, metabolic syndrome and hypertension, which will further 
contribute to increases in treatment-related morbidity and mortality (Epping & Black, 2016; 
Kruse & Schulz, 2016). Due to the fact that individuals with SSDs take antipsychotic 
medications to manage symptoms of these incurable disorders, most individuals will be on 
their prescriptions for decades, if not for life, exacerbating the negative side effects (Spertus, 
Horvitz-Lennon, Abing, & Normand, 2018). However, non-pharmaceutical interventions 
have proven to be helpful in managing the side effects of these medications (Dayabandara et 
al, 2017). 
It is important to recognize that while antipsychotic medications may be useful in 




mental, emotional and social wellbeing. Medications often make individuals feel sedated, 
decreasing overall energy and motivation levels (Connolly & Kelly, 2005; Joshi, Quadros, 
Drumm, Ain, & Panicker, 2016; Muench & Hamer, 2010).  
 These side effects, such as diabetes, hypertension and sedentary behavior are risk 
factors for comorbidities such as cardiovascular disease (CVD) (Wildgust & Beary, 2010). 
The most common cause of natural death amongst individuals with SSDs is CVD, which is 
similar to the general population (Brown, Inskip, & Barraclough, 2000; Hjorthøj, Stürup, 
McGrath & Nordentoft, 2017; Laursen, 2011), and is the biggest contributor to the 
population’s decreased life expectancy (Stubbs, Williams, Gaughran, & Craig, 2016). 
 
Section 3.1 Barriers to Physical Activity in SSDs 
The reasons that individuals with SSDs spend the majority of their waking hours 
extremely sedentary are multifaceted, including a number of cited barriers. Individuals with 
SSDs exhibit a lack of both energy and motivation, potentially due to sedative medications 
and negative symptoms (Connolly & Kelly, 2005). Tiredness and low energy levels are 
significantly higher in individuals with long-term SSDs compared to both the general 
population and individuals in the early stages of SSDs (Firth et al, 2016). Another important 
barrier that individuals with SSDs report is that they “may not feel sufficiently competent at 
physical activities, feeling either not physically fit enough or skilled enough to exercise, or 
they may have health limitations,” including poor health and physical illnesses that may 
present as barriers to physical activity (Teixeira, Carraca, Markland, Silva, & Ryan, 2012). 




further barriers to participation in exercise. The most reported barrier to exercise in 
individuals with SSDs is lack of motivation. Individuals that have had long-term SSDs report 
significantly greater levels of amotivation when it comes to engaging in physical activity 
when compared to the general population and individuals that have recently been diagnosed 
(Firth et al, 2016).  
Sedentary behavior may be due to the severity and uniqueness of the symptoms of 
these disorders. Individuals with SSDs are often isolated from society and become relatively 
reclusive due to shame and embarrassment of their condition (Connolly & Kelly, 2005). This 
is a factor discouraging individuals from leaving their homes, resulting in the population 
disengaging in regular daily activities. By creating a group-based walking program, designed 
specifically for this population, these individuals may be able to overcome this barrier. It 
would be helpful to create a positive group environment surrounding physical activity in 
order for indivudals diagnosed with SSDs to have a safe space to engage in exercise. 
Another potential cause of sedentary behavior is lack of available infrastructure. 
Individuals with SSDs are typically part of a lower socioeconomic class. This means that 
they may not live in an area where they feel safe to go outside and take advantage of parks or 
sidewalks in their neighborhoods, thus limiting the amount of physical activity that 
individuals with SSDs may feel compelled to engage in regularly (Connolly & Kelly, 2005). 
Beyond lack of available infrastructure, persons with SSDs oftentimes feel that they lack 
appropriate support, not only in their personal lives, but also from their healthcare 
professionals (Bredin, Warburton, & Langs, 2013; Ussher, Stanbury, Cheeseman, & 
Faulkner, 2005) or a partner to train with (Firth et al, 2016). A group-based walking program 




participate in physical activity by both making a place to walk and a group of individuals, 
including group leaders, to help encourage and support group participants available on a 
regular basis throughout the course of the intervention.  
Another important, also less reported, barrier to individuals with SSDs participating 
in physical activity is that they are oftentimes uninformed of the importance of being 
physically active and the dangers of regularly sedentary behavior (Connolly & Kelly, 2005). 
Individuals with SSDs lack the basic, yet important, information having to do with exercise 
(Firth et al, 2016). Individuals with SSDs have also reported significant rates of disinterest in 
exercise, however, there are few reports that individuals exhibit a fear of being unsafe or 
sustaining injury due to exercise (Firth et al, 2016). By making exercise specialists available 
to individuals with SSDs, a group lead by qualified trainers would be helpful to educate 
participants on the importance of becoming and remaining physical activity on a regular 
basis. 
Other notable barriers to participating in physical activity common among both the 
generally healthy population and the SSDs population include lack of time (Firth et al, 2016), 
poor weather, disturbances to current routines and dislike of exercise (Dunn, Marcus, 
Kampert, Garcia, Kohl, & Blair, 1999).  Therefore, through a compilation of factors, the 
SSDs population spends the majority of their waking hours four times more sedentary on a 
regular basis than the general population due to a plethora of barriers that they face daily. A 
group-based walking intervention with weekly meeting surrounding setting goals and 





Section 3.2 Exercise as a Potential Intervention and Longevity in SSDs 
One aspect that most treatment plans do not take into consideration for individuals 
diagnosed with SSDs is exercise. While there are noted benefits and incentives for this 
population to engage in physical activity, it is a part of treatment that remains to go under 
appreciated and under acknowledged (Firth et al, 2019). Physical activity is an important part 
of a balanced and healthful lifestyle in both healthy and clinical populations, but is often 
overlooked. As it has been well determined, individuals with SSDs are extremely sedentary, 
averaging 12.5 waking hours sedentary per day (Stubbs, Williams, Gaughran & Craig, 2016). 
Sedentary behavior is a well-known risk factor for many comorbid diseases, including 
cardiovascular disease, and may be combated through lifestyle changes, such as increasing 
time spent physically active. 
Physical activity has many known benefits in both the general population and clinical 
populations, such as individuals diagnosed with SSDs. Physical activity is known to improve 
lipid profiles, glucose tolerance, hypertension and obesity (Connolly & Kelly, 2005), each of 
which contributes to decreased risk for development of CVD. There are additional benefits of 
physical activity such as improved mental and emotional health (Rastad, Martin, & Åsenlo, 
2014). Overall, physical activity has the potential to improve many aspects of health and 
wellbeing, causing an overall improvement in quality of life, potentially creating an 
improvement in the average lifespan of an individual with an SSD. Exercise has been shown 
to improve clinical symptoms associated with SSDs as well, as reported by a systematic 




 Although there has been some research done in the area of exercise interventions in 
individuals with SMI, including SSDs, it continues to be an area that requires further 
investigation. The studies that have been completed have proven that exercise interventions 
are both feasible and illicit improvements in a number of parameters for individuals 
diagnosed with SSDs (Bartels et al, 2015; Daumit et al, 2013). However, each of these 
studies display several limitations that are important to make note of in order to fill the gaps 
in the current literature. For example, several studies in this field fail to evaluate in depth 
reports of adherence and compliance of individuals with SSDs to exercise intervention 
prescriptions, especially when subjects are being prescribed specific target HR ranges or 
minutes spent active per session or week.  
 In 2013, Daumit et al. administered a lifestyle intervention to provide individuals with 
SSDs an opportunity to attend group weight management sessions, individual weight 
management sessions and group exercise sessions in an effort to test whether or not subjects 
would successfully lose weight over the course of 18 months. The research team utilized 
social cognitive and behavioral self-management theories as well as environmental supports 
to help subjects set specific nutrition goals. Subjects also used a physical activity tracking 
device to monitor and report their daily behaviors. This study indicated that, when compared 
to a control group, subjects were able to lose a significant amount of weight. Some 
limitations noted in this study included decreased attendance over the course of the 
intervention, lack of power for analytical purposes, lack of control for medications and lack 
of monitoring diet, despite offering dietary counseling. Daumit and colleagues suggest that 
future research make note of these limitations when implementing targeted behavorial 




or rewarding subjects for participating in order to help increase adherence, powering the 
study for appropriate recruitment numbers, increasing control for medications that may affect 
weight loss, and monitoring diet through a simple tracking tool. At the time of the study, 
there had been limited research in this area however, Daumit et al’s findings help to support 
the continuation of research in weight-loss interventions for persons with SMIs.  
In 2015, Bartels et al. conducted a weight loss intervention program that provided a 
group of individuals with SSDs a free fitness club membership and health promotion coach, 
along with a personalized exercise and nutrition plan based on each individual’s goals. 
Individuals in the comparison group were offered the free gym membership. This study 
provided evidence that individuals with SSDs that start an exercise intervention with a BMI 
greater than 25 kg/m2 can lose a clinically significant amount of weight over the course of 
one year. This program, which was administered by routine care providers, indicated that it is 
feasible for mental health clinics to offer an exercise program to its clients. However, there 
were several limitations to this study, including lack of monitoring the control group’s 
physical activity levels and lack of sample size to be able to analyze differences in results 
between various diagnosis groups, genders and ethnicities. Using physical activity trackers to 
monitor all study participants would help to eliminate any amount of unknown activity that 
subjects may be engaging in.  
There are several other studies that indicate that exercise is capable of improving both 
physical fitness and cardiometabolic risk factors, specifically through aerobic exercise 
(McNamee, Mead, MacGuillvray, & Lawrie, 2013). There is empirical evidence that 
suggests that psychological symptoms, as well as levels of functioning, co-morbid disorders 




et al, 2015). Physical activity interventions are also proven to significantly reduce symptoms 
of SSDs as well as depression, along with improving anthropometric measures, 
cardiorespiratory fitness and quality of life (Rosenbaum et al, 2014).  
There have also been studies showing that walking for individuals with SSDs in 
several aspects of health, can improve cardiopulmonary fitness and mental and emotional 
wellbeing (Beebe et al, 2009; Browne, Penn, Battaglini, & Ludwig, 2016). Beebe et al. 
studied the effects of a group-based, supervised treadmill walking intervention that lasted 
sixteen weeks. Subjects in this study were expected to walk 30 minutes, three times a week at 
a target HR that was prescribed based on baseline HR values. The target HR was used to 
create an exercise dose-response with the goal of maximizing the benefits of the walking 
intervention. This study helped to lay the groundwork for a group-based walking intervention 
at local mental health clinics by Browne et al. While a small sample, the intervention done by 
Browne, et al., in 2016 provided evidence that group-based walking sessions held at local 
mental health clinics may be accessible to a number of individuals with SSDs. This method 
of providing an intervention to individuals with SSDs provides solutions to several barriers 
often presented in this population. This study allowed subjects to feel a sense of community 
and support in their endeavor to increase engagement in physical activity, which is often 
known to help overcome many other barriers they may face towards exercise (Firth et al, 
2016). Overall, walking has been proven to be a safe and effective mode of activity for 
individuals diagnosed with SSDs to partake in to improve physical and mental wellbeing 
(Soundy, Muhamed, Stubbs, Probst, & Vancampfort, 2014). 
Beyond the research, subjects who have participated in physical activity have 




incentives to engage in physical activity including improvement in overall physical health 
and fitness as well as weight loss. Other notable improvements that individuals have reported 
with exercise include reduced stress levels and improved mood, reduced depression and 
improvement in overall psychological wellbeing (Firth et al, 2016). These are important 
incentives to note to help improve future research within this developing field of exercise 
psychology for individuals diagnosed with SSDs.  
 
Summary 
 There is a growing literature involving individuals with SSDs participating in 
interventions aimed to improve regular physical activity participation. Preliminary studies 
examining the role of physical activity participation in the form of walking has shown it to be 
accessible, preferable and may yield physiological benefits in persons diagnosed with SSDs 
(Soundy et al., 2014). These types of interventions are also successful in addressing various 
barriers that individuals with SSDs face in terms of being physically active, including 




CHAPTER THREE: METHODOLOGY 
Research Design Overview 
 PACE-Life (Physical Activity Can Enhance Life) was approved by the Institutional 
Review Board at UNC Chapel Hill. During this open trial, subjects were enrolled in a 
walking intervention that met biweekly over the course of six months. Subjects were 
expected to attend as many groups as they were able to. Subjects were also expected to 
complete four rounds of assessments – one prior to the 6-month walking group intervention 
(baseline assessment), one 3-months into the intervention (mid-treatment assessment), one 
post-intervention (post-treatment assessment) and one 1-month following the termination of 
the intervention (1-month follow up assessment), as depicted in Diagram 1. These 
assessments took place at UNC Chapel Hill Hospital, in the Department of Exercise and 
Sport Science at UNC, and at either the Carrboro or Raleigh STEP clinics. Along with group 
walks, subjects also attended goal setting and if-then planning sessions during the second 
group of each week. These sessions were used to help subjects determine appropriate step 
and home-based walking goals along with assist subjects in brainstorming possible solutions 
to navigate around everyday obstacles that interfere with participating in physical activity. In 
addition to group walking sessions, subjects were also encouraged to complete home-based  
“intensity walks,” beginning after the seventh week of the intervention. Intensity walks are 
independent walking sessions that the subjects were to complete outside of group sessions.  
Subjects were also given a Fitbit Charge HR to be worn during all waking hours for the 
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duration of the study, including during walks, which helped subjects monitor their HR during 
activity.  For both group walks and intensity walks, each subject was given an individualized 
target heart rate range using the heart rate reserve method, based on resting heart rate and age 





Inclusion/exclusion criteria were as follows: (i) subjects presented with a formal 
diagnosis of a Schizophrenia Spectrum including Schizophrenia, Schizoaffective Disorder, 
Brief Psychotic Disorder, Schizophreniform Disorder, and Unspecified Schizophrenia 
Spectrum and Other Psychotic Disorders based on the Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition (American Psychiatric Association, 2016); (ii) subjects were at 











stable with no medication alterations one month prior to enrollment; (iv) subjects had no 
psychiatric related hospitalizations three months prior to enrollment; (v) subjects were not 
already engaging consistently in moderate-intensity exercise for at least 60 minutes per week 
over the 6 months prior to enrollment; (vi) subjects presented with no contra-indications to 
engage in regular, moderate-intensity exercised as defined by the American College of Sports 
Medicine (ACSM) guidelines (Exercise Preparticipation Health Screening, 2018); (vii) 
subjects scored an IQ of at least 70 as  assessed via the Wechsler Abbreviated Scale of 
Intelligence (WASI) (see Appendix 3.1); (viii) subjects were not pregnant nor did they 
become pregnant throughout the duration of the study; (ix) subjects were willing and able to 
provide informed consent to participate in the study.  
 
Recruitment and Enrollment Procedures 
 Subjects were recruited through UNC STEP clinics located in Raleigh and Carrboro, 
via healthcare professionals, such as clinicians, psychiatrists and nurses, and signage, 
including flyers (see Appendix 3.2). Individuals that had given permission previously to be 
contacted for future studies were telephoned and/or emailed directly. Once a participant 
showed interest and gave permission they were screened via phone call (see Appendix 3.3). 
A Physical Activity Readiness Questionnaire (PAR-Q) (see Appendix 3.4) and a Medical 
History and Physical Exam Form (see Appendix 3.5) were used to determine if it was safe 
for subjects to participate in exercise. A Demographic Form, including a Medications and 
Supplements report (see Appendix 3.6) was used to acquire further information about 




Exercise Training Intervention 
 Once subjects were enrolled in the study, they participated in the exercise training 
intervention in the form of walking groups. The intervention included group based 
community walks lasting 30 minutes, twice a week at a target heart rate based on heart rate 
reserve according to a resting heart rate acquired during the baseline assessment or through 
each participant’s Fitbit. Heart rate ranges were adjusted and progressed accordingly to 
Table 1 every three weeks over the course of six months. Group walks remained consistent 
at twice a week, while intensity walks were assigned starting in the seventh week and 
progressed from one to three walks over the following 18 weeks. The goal of this volume 
progression was to increase minutes of activity completed so that subjects were participating 
in at least 150 minutes of moderate intensity activity a week, as recommended by ACSM, by 
the end of the intervention. 
 
Week %HRR Sessions Intensity Walks 
1-3 50-60% 2 0 
4-6 50-65% 2 0 
7-9 60-65% 2 1 
10-12 65-70% 2 1 
13-15 65-70% 2 2 
16-18 65-70% 2 2 
19-21 70% 2 3 
22-24 70%          2           3 







Primary Purpose Methodology  
 For the purposes of assessing adherence, both group attendance and Fitbit data were 
collected. Subjects were asked to attend as many of the walking group sessions as they were 
able to. Attendance was taken by group leaders at each session. Along with attending 
walking groups, subjects were also asked to wear a Fitbit during all waking hours for the 
duration of the intervention. The group leaders synced Fitbits to mobile devices at the start 
and end of each walking sessions. The research team member administering assessments also 
synced subjects’ Fitbits. Some, but not all, of the subjects were able to sync their devices on 
their own and did so regularly. Throughout the study, the Fitbit data was logged from each 
subjects’ online account into a separate Excel file. Information pulled included resting heart 
rate, daily steps, bouts of activity including date and time of activity, type of activity, number 
of steps taken during the active bout, duration of activity (active minutes) and heart rate 
associate with each bout of activity. Days on which subjects completed at least 300 steps 
were counted as “present” while days on which subjects did not complete 300 steps were 
counted as “absent.”  
 For the purposes of assessing compliance, HR was assessed via Fitbit, which was 
recorded from each subject’s online profile and compared to the prescribed HR for the 
appropriate time period. This was done for both group-based walks as well as walks at home, 
which were considered to be independent, intensity walks. If the active HR was within the 
target range then it was counted towards being compliant for those active minutes. If the 
active HR was less than the target range, then the active minutes were not counted towards 
being compliant in respect to the prescribed HR training zone. To assess the third component 




prescribed overall, the total number of active minutes prescribed was compared to the overall 
number of active minutes completed by the subject, regardless of HR during active bouts.  
 
Secondary Purpose Methodology 
 Resting heart rate and blood pressure, height and weight, hip and waist 
circumferences (see Appendix 3.7) and the 6-minute walk test (see Appendix 3.8) were 
physiological outcomes evaluated as secondary outcomes of this study. Resting heart rate and 
blood pressure were assessed after the subject had been seated quietly in a dimmed room for 
at least five to ten minutes. Heart rate was assessed via radial palpation and blood pressure 
using a stethoscope (Prestige Medical, Northridge, CA) and sphygmomanometer (American 
Diagnostic Corporate, Hauppauge, NY). Subjects were assessed without shoes during height 
and weight measurements using a physician balance beam scale (Detecto, Webb City, MO) 
with height rod. Subjects were assessed standing straight, feet together and arms relaxed, 
using a tape measure (Dritz, Spartanburg, SC). For the 6MWT subjects were asked to walk as 
far as possible, without running, for 6 minutes up and down a hallway around cones 
measured 100 feet apart, outside of the Exercise Oncology Research Lab in Fetzer Hall, 
Department of Exercise and Sport Science at UNC Chapel Hill, or in the hallways of either 







Tertiary Purpose Methodology 
  The Basic Psychological Needs in Exercise Scale (BPNES) (see Appendix 3.9), the 
Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2) (see Appendix 3.10), and 
Physical Activity Enjoyment Scale (PACES) (see Appendix 3.11) were the psychological 
instruments used for the evaluation of the tertiary purpose of this study. The BPNES and 
BREQ-2 are both questionnaires containing items rated on 5-point Likert scales. The BPNES 
has responses ranging from 1 (I don’t agree at all) to 5 (I completely agree), while the 
BREQ-2 has responses ranging from 0 (Not true for me) to 4 (Very true for me). The BPNES 
is sub-scored into three components: Autonomy (questions 2, 5, 8 and 11), competence 
(questions 1, 3, 6 and 9) and relatedness (questions 4, 7 and 10). The average score of each 
question was used to determine the mean for each component. The BPNES assesses how 
well exercise meets an individual’s needs for autonomy, competence and relationship 
(Vlachopoulos, Ntoumanis & Smith, 2010). The BREQ-2 assesses an individual’s 
amotivation (questions 5, 9, 12 and 19), external regulation (questions 1, 6, 11, and 16), 
introjected regulation (questions 2, 7 and 13), identified regulation (3, 8, 14 and 17) and 
intrinsic regulation (4, 10, 15 and 18). Each of these components are averaged and then 
weighted accordingly: Amotivation (-3), external regulation (-2), introjected regulation (-1), 
identified regulation (+2), and intrinsic regulation (+3). The sum of these values is computed 
to determine the overall Relative Autonomy Index (RAI) score. Both the BPNES and BREQ-
2 have proven to be appropriate and valid assessment tools for evaluating motivation for 
physical activity (Vlachopoulos & Michailidou, 2006). PACES is a questionnaire which 
makes two opposing statements of different perceptions of exercise and asks subjects to rank 




associated with a more positive association towards exercise (Kendzierski & DeCarlo, 1991). 
PACES is a valid measure for gauging an individual’s perceptions towards physical activity 
in general (Mullen et al., 2011). The score for this questionnaire is an overall sum from each 
question’s raw score. Finally, an Exit Survey (see Appendix 3.12) was also used in the final 
assessment stage to gather further information regarding attitudes and barriers towards 
physical activity and the intervention overall. 
 
Statistical Analysis and Design 
 All data were analyzed via Jamovi Version 1.0.8.0 (The jamovi project, 2019). 
Descriptive statistics, including means and standard deviations, were calculated for all 
biological and physical function measurements, and physical activity data gathered from 
participant Fitbits. The alpha level for statistical analyses was set a priori at ≤.05. A power 
analysis was not conducted due to the novelty of the study and lack of available data 
regarding the population and intervention. It is hopeful that the results of this study will assist 
in power analyses of future studies. 
H1: Subjects participating in a 6-month walking intervention will have adherence and 
compliance rates of 50%.  Adherence was determined by calculating the averages of 
group attendance rates and days Fitbit was worn. Compliance was assessed in three 
ways: (1) percentage of minutes spent within the prescribed HR range at group 
walking sessions, (2) percentage of minutes spent within the prescribed HR range 





H2: Assuming subjects adhered to at least 50% of the training prescription, functional 
and health-related outcomes including 6MWT, resting heart rate, resting blood 
pressure, mean arterial pressure, hip and waist circumferences and waist to hip ratio, 
body mass index and weight will improve significantly in individuals with SSDs over 
a 6-month exercise intervention. It is believed that 50% of the prescribed amount of 
activity is a reasonable amount to elicit improvements in these measures based on 
adherence and compliance rates reported in the literature. The second hypothesis was 
analyzed using one-way ANOVAs with repeated measures using three timepoints 
(baseline, mid-treatment and post-treatment assessments). If significance was 
observed, a post hoc Tukey test was conducted. No Bonferroni adjustment was made 
due to the fact that these results are preliminary. Effect size was also computed for all 
analyses. The effect size of each post hoc analysis was computed via the 
Cohen’s d method (small effect size, d = .2 - .5: medium effect size, d = .5 - .8: large 
effect size, d  > .8).  
H3: Motivation towards physical activity and exercise would improve over the course 
of a 6-month exercise intervention. The third hypothesis was analyzed using one-way 
ANOVAs with repeated measures, using three timepoints (baseline, mid-treatment 
and post-treatment assessments), comparing answers from previously described 
questionnaires, including the BPNES (autonomy, competence and relatedness), 
BREQ-2 (amotivation, external regulation, introjected regulation, identified 
regulation, intrinsic regulation, and relative autonomy index score) and PACES. If 
significance was observed, a post hoc Tukey test was run. Effect size was calculated 




gathered from the Exit Survey.
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CHAPTER FOUR: RESULTS 
Overview 
 The primary purpose of this study was to determine the adherence and compliance of 
individuals diagnosed with SSDs to a 6-month, group-based walking intervention held at 
local mental health clinics. The secondary purpose of the study was to analyze if the 6-month 
intervention would impact physical functional and health-related outcomes in individuals 
with SSDs. The tertiary purpose of this study was to evaluate any effects on subjects’ 
motivation towards exercise after completing the intervention.  
 
Subjects 
 Seventeen subjects were recruited at the beginning of the study. Sixteen subjects 
completed the study. One subject voluntarily withdrew from the study due to non-study 
related psychiatric health deterioration. Therefore, 16 subjects are included in the analyses, as 
shown in Diagram 2. Demographics of the study subjects are presented in Table 2. 
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Average Age 38.2 ± 11.7 years 
Gender 62.50% Males 
37.50% Females  
Race 56.25% Caucasian  
18.75% Black/African American 
6.25% Asian 
6.25% Native Hawaiian or Other Pacific 
            Islander  
6.25% American Indian or Alaskan Native 
6.25% Other 
Ethnicity 100% Non Hispanic or Latino 
Education 6.25% Some high school 
12.50% High school diploma or equivalent 
56.25% Some college 
12.50% College degree 
12.50% Higher than college 
Estimated Years of Education 14.73 ± 3.78 
Mother’s Education 18.75% High school diploma or equivalent 
12.50% Some college 
31.25% College degree 
37.50% Higher than college 
Estimated Years of Mother’s 
Education 
15.61 ± 2.29 
Father’s Education 6.25% Middle school or less 
6.25% High school diploma or equivalent 
12.50% Some college 
25.00% College degree 
43.75% Higher than college 
Estimated Years of Father’s 
Education 
15.6 ± 3.50 
Smoker 43.75% 
History of Substance Abuse 31.25% 
History of Substance Dependence 25.00%  








Primary Purpose Results  
 The primary purpose evaluated the overall adherence and compliance of the 6-month 
walking intervention by calculating the percentage of group walking sessions attended and 
the percentage of time subjects wore their Fitbits over the entire intervention. Compliance 
was calculated by determining the percentage of time subjects spent within the prescribed 
heart rate range during both group walking sessions and independent intensity walking 
sessions. Compliance was also calculated by determining the percentage of active minutes 
completed compared to the amount of active minutes prescribed. Results for adherence and 
compliance are summarized in Table 3.  
 












Adherence    
Group Attendance 12 4 34% 
Device Adherence 9 7 51% 
Compliance   
Active Minutes 4 10 179% 
Group HR 13 1 4.9% 
Home-based HR 13 1 0.6% 
Table 3: Adherence and Compliance Results Summary 
 
Adherence 
 The overall group attendance rate was 34%, while overall, subjects worn their Fitbits 
51% of the time. However, 25% of subjects attended at least half of all walking group 




Overall adherence was evaluated as 25% of subjects having attended at least half of all 
groups and having worn their Fitbits half of the prescribed days, about 19% of subjects did 
not attend at least half of all walking sessions but wore their Fitbit half of the prescribed 
days, and about 56% of subjects neither attended at least half of all groups nor did they wear 
their Fitbit at least half of the prescribed days. Adherence results are summarized in Table 4. 
 
Overall Level of Adherence Number of Subjects 
Attended at least 50% of groups and worn Fitbit for at least 
50% of prescribed time 
4 
Attended at least 50% of groups but did not wear Fitbit 50% of 
prescribed time 
0 
Wore Fitbit 50% of prescribed time but did not attend 50% of 
group sessions 
3 
Did not attend at least 50% of groups or wear Fitbit for 50% of 
prescribed time 
9 
Table 4: Summary of Adherence Results 
 
Compliance 
  For compliance analyses, only 14 of the 16 subjects were included. The two subject 
excluded from compliance analyses chose not to wear the Fitbit throughout the course of the 
study, and it is therefore unknown if they complied with the exercise prescription. For the 14 
subjects included in analyses, a much greater number of overall active minutes than 
prescribed was observed (179% of prescribed active minutes). However, only 71% of 
subjects completed at least 50% of active minutes prescribed while 29% of subjects 
completed less than 50% of active minutes prescribed. Only about 7% of subjects were 
within the target heart rate range for at least 50% of active minutes completed during group 




50% of active minutes completed during group walks. About 7% of subjects were within the 
target heart rate range for at least 50% of active minutes completed during home-based walks 
while the other 93% were within the target heart rate range for less than 50% of active 
minutes completed during home-based independent intensity walks. Compliance results are 
summarized in Table 5. 
  
Level of Compliance Number of Subjects 
Completed at least 50% of active minutes prescribed but did 
not comply with HR ranges for group-based, nor home-based 
walking sessions 
8 
Completed at least 50% of active minutes prescribed, complied 
with at least 50% HR ranges for group-based, but not home-
based walking sessions 
1 
Completed at least 50% of active minutes prescribed, complied 
with at least 50% HR ranges for home-based, but not group-
based walking sessions 
1 
Did not complete at least 50% of active minutes and also did 
not comply with HR ranges for group-based, nor home-based 
walking sessions 
4 
Fitbit did not record any number of active minutes (subjects 
not included in analyses for compliance) 
2 
Table 5: Summary of Compliance Results 
 
Secondary Purpose Results 
 Functional and health-related outcomes would improve significantly over the course 
of the 6-month walking intervention, which was analyzed using one-way ANOVAs with 
repeated measures. Measures that were assessed included 6MWT, waist to hip ratio, resting 
BP, MAP, RHR, weight and BMI. Results for functional and physiological parameters are 














     
6MWT (m) 377 ± 112*∞ 465  ± 114* 466  ± 128∞ 0.001 0.142 
Anthropometrics      
Waist (cm) 103 ± 24.0 104 ± 24.3 107  ± 23.9 0.425 0.003 
Hip (cm) 115 ± 20.7 114 ± 16.7 117  ± 19.7 0.683 0.002 




0.915  ± 
0.092 
0.803 0.004 
Body Weight (kg) 94.4 ± 30.6 94.9 ± 32.3 97.3  ± 32.0 0.513 0.000 
BMI (kg/m2) 31.6 ± 9.38 32.0 ± 9.90 32.6  ± 9.62 0.785 0.000 
Resting 
Hemodynamics 
     
RHR (bpm) 78.1 ± 17.8 85.3 ± 14.6 80.8 ± 16.3 0.470 0.018 
RSBP (mmHg) 109 ± 11.9 108 ± 13.1 111  ± 12.1 0.578 0.008 
RDBP (mmHg) 74.4 ± 11.5 74.5 ± 13.3 79.7  ± 11.3 0.199 0.039 
MAP (mmHg) 85.9 ± 10.5 85.7 ± 12.0 90.2  ± 11.0 0.166 0.030 
Table 6: Functional and Physiological Parameters Results:  
** Significant differences in 6-minute walk distances between baseline and mid-treatment (377 ± 112 m, 
465  ± 114, p < 0.001, and ∞ baseline and post-treatment (377 ± 112 m, 466  ± 128 m, p < 0.001). 
Note: 6MWT = 6-Minute Walk Test. W: H Ratio = Waist to hip ratio. BMI = Body mass index. RHR = 
Resting heart rate. RSBP = Resting systolic blood pressure. RDBP = Resting diastolic blood pressure. 
MAP = Mean arterial pressure. 
 
Functional Assessment  
At baseline, subjects averaged a distance 377 ± 112 m walked. At mid-treatment, 
subjects averaged 465  ± 114 m walked. At post-treatment, subjects averaged 466  ± 128 m 
walked. A significant ANOVA model was observed (p < 0.001, ES = 0.142). Post hoc 
analyses revealed significant differences in 6-minute walk distances between baseline and 
mid-treatment (377 ± 112 m, 465  ± 114, p = 0.001), as well as baseline and post-treatment 






As reported in Table 6 above there were no significant findings observed from 
baseline, mid-treatment and post-treatment assessments for any of the physiological 
parameters, including anthropometric measures such as waist and hip circumferences, waist 
to hip ratio, as well as resting hemodynamics, including resting BP, MAP, RHR, weight and 
BMI. 
 
Tertiary Purpose Results 
 For the third purpose of the study, it was hypothesized that subjects’ motivation 
towards physical activity would improve significantly over the course of the 6-month 
walking intervention. This hypothesis was analyzed using repeated measures ANOVAs. The 
results for the analyses of motivation towards physical activity evaluated using the BPNES, 




















BPNES      
Autonomy 3.00 ± 1.10*Φ 3.70 ± 0.745* 3.77  ± 0.697Φ 0.014 0.147 
Competence 3.16 ± 1.08 3.50 ± 0.641 3.35  ± 0.885 0.143 0.066 
Relatedness 2.37 ± 1.22∞	τ 3.27 ± 0.856∞ 3.44 ± 0.981τ 0.011 0.16 
BREQ-2      
Amotivation 0.391 ± 0.652 0.483 ± 0.513 0.517 ± 0.691 0.868 0.005 
External 
Regulation 
1.25 ± 0.913 0.967 ± 0.807 1.25 ± 1.00 0.287 0.030 
Introjected 
Regulation 
1.58 ± 1.29 1.62 ± 1.03 1.62 ± 1.08 0.887 0.002 
Identified 
Regulation 
2.78 ± 0.999 3.03 ± 0.700 2.95 ± 0.862 0.053 0.027 
Intrinsic 
Regulation 
2.70 ± 1.26° 3.17 ± 0.659° 2.82 ± 0.770 0.014 0.080 
RAI 8.42 ± 6.86 10.60 ± 4.73 8.68 ± 4.87 0.127 0.057 
PACES      
Overall 
Score 
92.8 ± 15.2 86.8 ± 30.0 87.5 ± 27.6 0.715 0.012 
Table 7: Psychometric Questionnaire Results 
* Significant differences for autonomy on the BPNES between baseline and mid-treatment (3.00 ± 1.10, 
3.70 ± 0.745, respectively, p = 0.038); Φ  Significant differences for autonomy on the BPNES between 
baseline and post-treatment (3.00 ± 1.10, 3.77  ± 0.697, respectively, p = 0.021), ∞ Significant differences 
for relatedness on the BPNES between baseline and mid-treatment treatment (2.37 ± 1.22, 3.27 ± 0.856, 
respectively, p = 0.040); τ  Significant differences for relatedness on the BPNES baseline and post-
treatment (2.37 ± 1.22, 3.44 ± 0.981, respectively, p = 0.014); ° Significant differences for intrinsic 
regulation on the BREQ-2 between baseline and mid-treatment (2.70 ± 1.26, 3.17 ± 0.659, respectively, p 
= 0.011).  
Note: BPNES = Basic Psychological Needs Scale. BREQ-2 = Behavioral Regulation in Exercise 
Questionnaire. PACES = Physical Activity Enjoyment Scale. 
 
Basic Psychological Needs in Exercise Scale 
At baseline, subjects averaged a score of 3.00 ± 1.10 for autonomy on the BPNES. At 
mid-treatment, subjects averaged a score of 3.70 ± 0.745 for autonomy on the BPNES. At 




significant ANOVA model was observed (p = 0.014, ES = 0.147). Post hoc analyses 
indicated significant differences for autonomy on the BPNES between baseline and 
midtreatment (3.00 ± 1.10, 3.70 ± 0.745, respectively, p = 0.038) and between baseline and 
post-treatment (3.00 ± 1.10, 3.77  ± 0.697, respectively, p = 0.021).  
At baseline, subjects averaged a score of 2.37 ± 1.22 for relatedness on the BPNES. 
At mid-treatment, subjects averaged a score of 3.27 ± 0.856 for relatedness on the BPNES. 
At post-treatment, subjects averaged a score of 3.44 ± 0.981 for relatedness on the BPNES. A 
significant ANOVA model was observed (p = 0.011, ES = 0.160). Post hoc analyses were 
conducted and significant differences for relatedness on the BPNES were observed between 
baseline and mid-treatment treatment (2.37 ± 1.22, 3.27 ± 0.856, respectively, p = 0.040) and 
between baseline and post-treatment (2.37 ± 1.22, 3.44 ± 0.981, respectively, p = 0.014).  
As reported in Table 7, there were no significant findings observed in competence 
between baseline, mid-treatment and post-treatment assessments.  
 
Behavioral Regulation in Exercise Questionnaire-2 
As reported in Table 7, there were no significant findings observed in amotivation, 
external regulation, introjected regulation or identified regulation between baseline, mid-
treatment and post-treatment assessments. There also was no significance observed in RAI 
between the three assessment periods. 
At baseline, subjects averaged a score of 2.70 ± 1.26 for intrinsic regulation on the 
BREQ-2. At mid-treatment, subjects averaged a score of 3.17 ± 0.659 for intrinsic regulation 
on the BREQ-2. At post-treatment, subjects averaged a score of 2.82 ± 0.770 for intrinsic 




regulation (p = 0.014, ES = 0.080). A post hoc test was conducted and a significance 
difference between baseline and mid-treatment were observed (2.70 ± 1.26, 3.17 ± 0.659, 
respectively, p = 0.011).  
 
Physical Activity Enjoyment Scale 
The ANOVA model was not significant, therefore no significant differences on the on 
the PACES questionnaire throughout the study were observed. 
 
Subject Exit Survey 
 The results from the exit survey were encouraging, with the overall average of each 
Likert scale question (1-18) being 4.3 out of 5, indicating that subjects had positive feelings 
towards the intervention and research experience. The highest rated question was reported at 
4.8 out of 5.0, indicating that subjects felt very included in conversations during group. The 
lowest ranked question was reported at 3.8 out of 5.0, indicating that subjects only 
moderately enjoyed tracking their active heart rates during walking groups. The Likert scale 
question results are summarized in Table 8. 
Subjects reported that the top reasons for missing group were issues with 
transportation and the outside temperature being too hot. The second most common reasons 
for missing group included having to go to work or school at the same time that group was 
held, not feeling well physically and not feeling well emotionally. Other reasons for having 
missed group included family obligations, other appointments, lack of compensation for 




Subjects reported that the number primary reason for not wearing their Fitbit was due 
to forgetting to put it back on after charging, with the second most common reasons being 
forgetting to put it on after sleep and dislike of monitoring physical activity.  
Subjects reported that the social interaction, incentive to meet goals and see results, 
and enjoyment of the group walks were what they liked the most about PACE-Life. Subjects 
reported that the thing they disliked the most about participating in PACE-Life was having to 
walk outside in various weather conditions, including the rain and summer heat. Subjects 
also reported dislike of group leaders changing with lack of consistency, along with general 
dislike of using a Fitbit device, and dislike of having to keep up with other members in group 
that walked at a faster pace. The subject exit survey’s open response results are summarized 
















Exit Survey Question Average Reported 
Value 
1. I enjoyed being part of a group focused on physical activity 
and health. 
4.4 ± 0.92 
2. Overall, I enjoyed goal-setting/if-then plan sessions once a 
week. 
4.4 ± 0.92 
3. I felt included in conversations during group. 4.8 ± 0.46 
4. I had a good relationship with the other members of the group. 4.4 ± 0.74 
5. I was motivated to attend groups because of the social 
interaction. 
4.0 ± 1.12 
6. I had a good relationship with the walking group leaders. 4.6 ± 0.74 
7. I felt motivated by group leaders during walking. 4.6 ± 0.74 
8. I was motivated to attend groups because of the health 
benefits I would gain from walking. 
4.4 ± 0.53 
9. I enjoyed using a Fitbit to track my physical activity. 4.2 ± 1.30 
10. I found the Fitbit easy to use. 4.3 ± 0.50 
11. I am likely to continue to use my Fitbit after the study ends. 4.0 ± 1.41 
12. I enjoyed tracking my heart rate during walks. 3.8 ± 0.83 
13. I enjoyed receiving target heart rate goals throughout the 
study. 
4.0 ± 0.87 
14. I felt the target heart rate goals were attainable for me. 4.2 ± 0.97 
15. I enjoyed setting goals for home-based intensity walks. 4.3 ± 0.71 
16. I felt that my if-then plans helped me overcome barriers to 
walking. 
4.2 ± 0.67 
17. Overall, I feel that my health has improved since joining 
PACE-Life. 
4.4 ± 0.88 
18. If given the chance, I would join PACE-Life again. 4.3 ± 1.12 
Table 8: Exit Survey Likert Scale Results
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Exit Survey Question Subject Response 
20. I missed group due to the 
following reasons: 
1. Issues with transportation 
2. Temperature being too hot outside 
3. Having to go to work or school at the same time 
4. Not feeling well physically 
5. Not feeling well emotionally 
6. Family obligations 
7. Appointments (scheduling conflict) 
8. Lack of compensation for attending 
9. Dislike of tracking physical activity 
23. I did not wear my Fitbit 
due to the following reasons: 
1. I forgot to put it on after charging it 
2. I forgot to put it on after taking it off to sleep 
3. I found it uncomfortable to wear 
4. It did not work well 
5. I did not like having my physical activity         
monitored 
6. Did not wear it on weekends when being inactive 
25. What I liked most about 
PACE-Life is... 
1. Social interaction 
2. Results 
3. Meeting goals 
4. Group walks 
26. What I liked least about 
PACE-Life is... 
1. Having to walk outside in poor weather 
2. Change/inconsistency of group leaders 
3. Difficulty keeping up with faster walkers in the 
group 
4. Disliked using Fitbit 
Table 9: Exit Survey Qualitative Response Summary
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CHAPTER FIVE: DISCUSSION AND CONCLUSION 
Overview 
 The purpose of this study was to determine the adherence and compliance of 
individuals with SSDs to a 6-month walking, group-based intervention that met biweekly at 
local mental health clinics. Analyses showed that adherence to the PACE-Life study, 
including group walking sessions and Fitbit adherence was 34% and 51% respectively. 
Compliance to the exercise prescription’s individualized target heart rate ranges in both 
group walks and during home-based walks were 4.9% and 0.6% respectively. Compliance to 
the overall total number of active minutes completed was 179% of the prescribed minutes. 
Further, the effects of the walking intervention on various physical parameters (i.e. 6MWT, 
RHR, resting BP, MAP, BMI, weight, hip and waist circumferences and waist to hip ratio), 
and psychometrics (i.e. BREQ-2, PACES, and BPNES) from baseline to mid-treatment and 
post-treatment assessments was also evaluated. Lastly, physical activity enjoyment was also 
evaluated objectively through different questionnaires and also subjectively through an exit 
participation survey. Significant improvements in 6MWT distance, autonomy, relatedness 
and intrinsic regulation were observed. 
 
Primary Purpose 
The primary purpose of this study was to analyze both adherence and compliance of 
individuals with SSDs to the PACE-Life program, a 6-month walking intervention. Overall 
adherence rates were lower than hypothesized (34% for group sessions attended – 25% of
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subjects attended at least 50% of group sessions; 51% for days Fitbit worn – 44% of subjects 
wore Fitbit at least 50% of days prescribed), especially compared to a similar pilot study 
done in 2016, which had a group attendance rate of 84% and a pedometer adherence rate of 
86% (Browne, et al, 2016). In Browne et al.’s study (2016) the intervention was only 10 
weeks long, in comparison to the current study’s length of 24 weeks. The 2014 study also 
financially compensated subjects $10 for every group session attended, incentivizing subjects 
to participate, which was not included in the present study. The adherence rates seen in the 
current study were also less than those seen in most studies included in the systematic review 
and Meta analysis done by Firth et al. in 2015. The exercise interventions that this review 
reported on that were done in individuals diagnosed with SSDs reported adherence rates 
upwards of 70%, with the exception of two studies, one done in 2003 by Archie et al. and 
one completed by Abdel-Baki et al. (2013). Archie et al. reported an attendance rate of 48% 
over the course of a 14 week, supervised walking intervention while Abdel-Baki et al. 
reported an attendance rate of 30% of the course of a 24 week intervention providing subjects 
free, unsupervised, gym access.  
Something else to consider when assessing adherence rates to PACE-Life are the 
changes from the first half of the intervention to the second half. Adherence to group sessions 
decreased from about 46% in the first three months (63% of subjects attended at least 50% of 
walking groups), to 22% (13% subjects attended at least 50% of walking groups) in the 
second half of the intervention. Adherence rates to group walking session reported in the 
current study may have been low due to the outdoor temperatures being too hot, especially in 
the second half of the intervention. Walking groups began in February and ended in August, 




high as 90 degree Fahrenheit. Due to the fact that groups were held predominantly outdoors 
in the area surrounding the mental health clinics, subjects may have been deterred from 
attending on days with extreme heat and humidity. This is in line with the information 
gathered from the exit survey, where subjects reported that one of the number one reasons for 
dislike of the PACE-Life study was having to walk outdoors in all weather conditions, 
including rain and heat. While one of the two locations where group was held had a 
convenient indoor location for inclement weather, including rain and heat, the other location 
did not experience this advantage, meaning that no matter outdoor conditions, groups were 
expected to be held in the outdoors. 
Another fact that subjects reportedly did not like about PACE-Life was the change in 
group walking leaders and inconsistently in research staff.  In the month of May, about 
halfway through the intervention, group leaders, which were primary graduate student 
research assistants, changed due to the end of the academic semester and change in 
work/school schedules. Due to the fact that individuals with SSDs typically dislike change 
and enjoy consistently in personnel, this may have contributed to a fall in attendance rates 
midway through the intervention. This may also help to explain why attendance rates 
decreased significantly from the first half of the program to the second. 
Another reason that subjects reported to have as a barrier to attending group included 
issues with transportation. Not all subjects had access to convenient transportation and 
therefore had a difficult time getting to/from the clinic to attend group. While some subjects 
were able to drive themselves, public transportation was also frequently used, but was not 
always accessible for all subjects. Other important, although less reported barriers, to 




other appointments taking place at the same time as group sessions; physical and mental 
unwellness; family obligations; lack of compensation; and dislike for tracking physical 
activity, which was encouraged during group walking sessions through the utilization of the 
Fitbit devices.  
Adherence to the Fitbits given to each subject was also low compared to other studies 
done utilizing physical activity tracking devices. One study designed to explore the 
feasibility of using wearable devices to monitor physical activity levels in a vulnerable, lower 
socioeconomic population, reported an 81% adherence rate, which is substantially higher 
than the current study’s reported device adherence rate (Yingling, et al, 2017). While 
advances in technology and wearable physical activity trackers makes it possible for remote 
interventions to be done, there are several notable limitations found in other studies that are 
also applicable to the low device adherence rates seen in the PACE-Life open trial. One 
notable limitation is that although the devices were gifted to subjects, not all individuals have 
access to the technology required to use the devices, such as computers or smart 
phones/mobile devices (Naslund, Marsch, McHugo & Bartels, 2015). Fitbits must be synced 
regularly in order for the data to be uploaded, however, if a subject does not have the means 
to sync the devices using Bluetooth technology, he or she may not have been obliged to wear 
the Fitbit at all.  This may be especially true if subjects were unable to attend walking group 
to have their Fitbits synced to their accounts for them by the group leaders, but was not 
something that was anticipated to be an issue prior to the start of the study. Another 
systematic review analyzing adherence to physical activity tracking devices, specifically 
utilized in patients with cardiovascular diseases, reported adherence rates from about 40% to 




reported rates of 86% in the first week of the intervention, and a decrease in adherence to 
74% by the end of the 12 week study (Swartz, et al, 2017). Each of these studies show the 
inconsistency, and decrease in adherence to wearable devices as the novelty of a new device 
wears off, supporting the low rates of device adherence in the current open trial. The current 
study faced a decreased Fitbit adherence from 63% in the first three months (71% of subjects 
adhered to wearing their Fitbit at least 50% of the prescribed time) to 43% in the second half 
of the PACE-Life intervention (50% of subjects adhered to wearing their Fitbit at least 50% 
of the prescribed time).  
Adherence of subjects wearing their Fitbits in the current study was significantly low 
for a number of reported and other possible, although not reported, reasons. Overall, subjects 
reported dislike of the physical sensation of wearing the Fitbit on their wrists. Others did not 
enjoy the appearance of the watch and felt that the red color drew too much attention to it, 
while also not coordinating with their other fashion choices. Another reason that subjects 
reported as to why they did not wear their Fitbit was due to a dislike of tracking physical 
activity. Other plausible reasons that subjects did not adhere to wearing their Fitbits may 
include the fact that the devices were of outdated technology and often did not charge, 
tracked information incorrectly, and displayed the incorrect information including date and 
time, and possibly HRs. According to the exit survey, the number one reason that subjects 
did not wear their Fitbit on a given day, however, was that they forgot to put it back on their 
wrist after taking it off to charge. Another significantly reported reason for not wearing the 
Fitbit was that subjects forgot to put it back on after taking it off at night to sleep.  
Overall compliance to the HR prescription portion of the PACE-Life study was low 




within HR range for at least 50% of active minutes completed in group walking sessions; 7% 
of subjects within HR range for at least 50% of active minutes completed during home-
based, independent intensity walks). However, compliance to active minutes prescribed was 
very high, significantly surpassing the prescribed dosage (179% overall active minutes 
completed). This may be due to the fact that subjects were gifted a Fitbit to track physical 
activity. Wearable devices to monitor an individual’s physical activity have been proven to 
increase time spent active (Brickwood, Watson, O’Brien & Williams, 2019). Providing 
individuals with a method to monitor activity, which subjects in PACE-Life reportedly 
enjoyed overall, often provides awareness of how little physical activity someone may be 
engaging in on a daily basis. This fact may have served as a wake up call to provoke subjects 
to participate in much more activity than anticipated overall, eliciting a “zero to one 
hundred” effect in some subjects.  
While several studies exist that prescribe specific exercise intensities for individuals 
with SSDs, it has become apparent that these studies oftentimes do not report the compliance 
of the subjects to prescribed intensities. It has also been noted that when prescribing target 
ranges and assessing compliance to pre-determined target exercise intensities, individuals 
with SSDs usually perform at a lower intensity than the general population (Bredin, 
Warburton, & Lang, 2013). However, PACE-Life may be compared to a physical therapy 
practice, in a sense that both involve subjects working with exercise specialists and then set 
recommendations for home-based exercises. Physical therapists oftentimes see 
noncompliance rates of up to 50% in their patients’ home-based recommended exercises 




PACE-Life, similarities of low compliance to recommended HR target training ranges during 
home-based intensity walk remains puzzling. 
Low compliance to HR prescription ranges may be due to a number of reasons in the 
current study. One possible explanation could be that the technology used to monitor HR 
throughout the study may have been inaccurate. If HR recorded as subjects’ resting values 
from the Fitbit trackers was incorrect, this could result in an inappropriate calculated range, 
which was determined using the HR reserve method. Each subject’s range may have been 
higher than appropriate for their potential “true” RHR. Subjects’ active HRs may also have 
been recorded inaccurately. HR values during activity were typically below the prescribed 
ranges according to Fitbit assessments. This may indicate that Fitbits underestimate HR 
values, but may also indicate that HR prescriptions were too high, and the intensity 
percentages, although appropriate in a general population for benefits of CRF and CV health, 
may have been greater than necessary for individuals with SSDs. Target HR ranges may also 
not have been achieved for the majority of active minutes due to lack of motivation, which is 
typically seen in this population of individuals. It is necessary that some level of motivation 
be met in order to walk at an intensity that is high enough to elicit a HR that will produce 
physiological changes in order to benefit CV health and reduce risk factors for CVD. 
Another possible explanation is that individuals with SSDs often experience decreased HR 
response to exercise, known as chronotropic incontinence (Herbsleb, et al, 2020). This 
phenomenon helps to explain why subjects may have struggled to achieve target HR ranges 
during walking sessions. It is also important to consider the fact that individuals with SSDs 
are often prescribed second-generation antipsychotic medications, which may alter heart 




HR response to exercise may be due to a decrease in ANS function and decreased HRV, as a 
direct result of antipsychotic medications blocking adrenergic and cholinergic receptors on 
both the heart and the blood vessels (Alvares, Quintana, Hickie & Guastella, 2016).  
 
Secondary Purpose 
 Despite low adherence rates, subjects experienced significant improvements in 
6MWT distances between baseline and mid-treatment, and mid-treatment and post-treatment. 
The improvement in 6MWT indicate potential improvements in CRF, which is one of the 
major goals of PACE-Life. The improvement in 6MWT distances may be due to the 
significant compliance rates to active minutes that subjects completed. Although subjects’ 
overall attendance rates were poor, 179% of active minutes prescribed were completed, 
indicating that subjects were physically active, even if it was not necessarily in the group 
setting. It also appears that, despite active HR values being below the prescribed range on 
average, increasing overall time spent active may have been sufficient to elicit an 
improvement in CRF in this population, which typically lives an extremely inactive and 
sedentary lifestyle. Improvements in cardiorespiratory fitness levels through an exercise 
intervention in individuals with SSDs are seen in several other studies that utilize walking 
based assessments (Beebe, et al, 2015; Heggelund, et al, 2012; Marzolini, et al, 2009).   
 While there was a significant improvement in 6MWT, there were no other significant 
physiological findings. This may be due to the lack of subject adherence to the prescribed 
exercise dosage, which would not allow for improvements in other physiological parameters 
to be seen. Each of these parameters would have required increased adherence and 




other parameters measured in the study. Improvements in health-related parameters from the 
PACE-Life study may have required increased intensity during time spent active, which was 
not achieved at this time.  
Increasing physical activity levels over 6-months was not sufficient to elicit changes 
in CV health parameters, such as RHR, and MAP. Differently from the current study, Abdel-
Baki et al. (2013), reported significant decreases in RHR, despite having an adherence rate of 
only 48% for the 14 week long intervention. The difference between Abdel-Baki and 
colleagues’ 2013 study and the current study may be attributed to the different exercise 
intensity used in these studies. In Abdel-Baki, the aerobic exercise prescription utilized both 
moderate and vigorous intensity ranges, whereas the PACE-Life study prescribed intensity 
varying from low to moderate intensities, which were prescribed only during the last 6 weeks 
of the intervention. Bredin et al., (2013) also reported improvements in CV parameters, 
including significant reductions in BP. While the exercise prescription in Bredin’s study was 
somewhat comparable to the current study, the adherence rates in Bredin et al.’s study were 
significantly higher than PACE-Life at 81% over the course of 12 weeks.  
The increase physical activity levels promoted over the 6-months intervention of 
PACE-Life may have not been sufficient enough to elicit changes in anthropometrics, such as 
circumference measures, weight and BMI. This is similar to the results seen in a systematic 
review and meta-analysis completed by Firth et al, (2015). Firth and colleagues’ review 
determined that exercise interventions in individuals with SSDs elicit inconsistent results in 
changes of anthropometric measures, such as weight and BMI. However, Firth et al. also 
noted that a decrease in waist circumference in this population might be a more important 




There are several other studies that report similar lack of changes in body weight and 
BMI (Heggelund, et al, 2011; Heggelund, et al, 2012; Marzolini, et al, 2009; Scheewe, et al, 
2013). Several studies implementing exercise interventions in this clinical population fail to 
report significant changes in waist circumference (Marzolini, et al, 2009; Scheewe et al, 
2013). In a couple of studies by Heggelund, et al, (2011, 2012), even with high adherence 
rates of 85% over the course of 8 weeks of intervention, no significant anthropometric 
changes had been observed. It may be assumed that the lack of changes in many of these 
studies may be due to the short intervention period. To further substantiate the potential lack 
of changes in these outcomes due to the short duration training protocols, Marzolini et al. 
(2009) did not find significant differences in anthropometrics, even when combining both 
aerobic and resistance training over the course of a 12 week period, an intervention that could 
have impacted more profound changes in anthropometrics. With the non-significant changes 
in any of the anthropometrics assessed in different students, modification on the mode, 
duration, and intensity of exercise along with the potential of combining exercise with 
nutritional manipulations are warranted for future experiments aiming for more robust 
changes on these parameters.  
 
Tertiary Purpose 
 Along with functional improvements, there were also several important 
improvements in various psychometric measures. These included improvements in autonomy 
and relatedness, as reported through the BPNES, along with improvements in intrinsic 
regulation, as reported through the BREQ-2. However, no significant changes were observed 




 Subjects reported increased feelings of relatedness over the course of the intervention, 
indicating that subjects felt better connected to other individuals from the start of the 
intervention to the completion of the 6-months of group sessions. These feelings were also 
consistent with those reported in the Exit Survey, where subjects highly reported feelings of 
good relationships between other group members as well as walking group leaders. Subjects 
also reported having felt motivated to attend group because of the social interaction that they 
gained from attending, indicating that they enjoyed the social support and interaction with 
other group members. This is consistent with the literature in that relatedness is strongly 
associated with group cohesion, and with positive group dynamics, individuals that are part 
of the group will improve feelings of relatedness over time, a fundamental and basic 
psychological principle (MacKenzie & Tschuscke, 1993).   
 Autonomy reportedly improved over the course of the 6-month study, indicating that 
subjects overall felt an improved sense of self-governance and independence with increased 
physical activity levels. The increase in reports of autonomy over the course of the study is in 
line with the work done by Klain, de Matos, Leitao, and Moutao in 2015. This study found 
that with increased support of physical educators, individuals felt greater levels of autonomy. 
Due to the fact that group walking session were led by trained research staff including 
exercise specialists, similar to physical educators, it is fitting the psychological needs in the 
forms of both relatedness and autonomy were further met from the start to the completion of 
the 6-month intervention. The support that subjects in PACE-Life gained from the group 





Finally, there were significant improvements in intrinsic regulation among subjects 
over the 6-month intervention period, indicating that subjects felt self-determined and driven 
by their own interest, motivation and enjoyment of engaging in physical activity. The results 
of the current study are similar to those of Vancampfort and colleagues (2015). The current 
study’s mid-treatment values were significantly improved from baseline values, indicating 
that subjects’ intrinsic motivation increased over the first three months of the study. 
However, there were no significant improvements from baseline to post-treatment, nor from 
mid-treatment to post-treatment. This may be due to the number of barriers identified 
explaining poor adherence rates, including weather and change in group leaders. Subjects 
may have lost motivation externally due to such obstacles and were unable to improve upon 
their intrinsic motivation then. It should also be noted that for most individuals with SMIs, 
internal motivation plays an important role in adapting, but also maintaining health 
promoting behaviors (Vancampfort et al, 2015).  
 
Conclusion 
Although the current study had a small sample size and was primarily a feasibility 
study with no control group, nor was it powered for analyses of physical and psychological 
function, several reasonable conclusions can be made from this open trial feasibility study. 
Firstly, overall adherence rates for this group-based walking intervention were relatively low, 
but compliance rates were high. Therefore, although adherence rates for the PACE-Life study 
were lesser than other exercise interventions completed by individuals diagnosed with SSDs, 
compliance for active minutes prescribed was substantial and may have contributed to the 




part the significant improvement on some of the psychometrics. Improvements in 
relatedness, autonomy and intrinsic regulation were observed. The overall experience of 
being part of this group-based walking intervention seemed pleasant, indicating that the 
major issue to be addressed for future trial is adherence, which appears to continue to be 
impacted by several barriers that this population experiences, thus limiting their ability to 
adequately engage in physical activity. 
 
Future Research 
 It is important that future research takes into account the limitations and barriers that 
the current study faced during the 6-month intervention. Adherence and compliance barriers 
need to be further addressed to improve overall exposure to the group walking sessions and 
intervention prescription. Methods to improve group attendance may include incentivizing 
subjects through financial compensation or points-based system to reward subjects for 
attending group sessions throughout the study. With increased group attendance may come 
increased motivation to comply with the exercise prescription, including the individualized 
HR range as well as the recommended home-based intensity walks. If subjects attend more 
regularly, they may feel more committed to the project and more keen to comply with other 
portions of the project.  
Another issue that must be addressed in future research includes subjects’ adherence 
to physical activity trackers, such as the Fitbit used in the current study. A few possible ways 
to improve adherence in this area is to utilize up-to-date technology, with features beyond 
physical activity tracking such as the capability to receive and answer calls and texts from a 




staff contact. Since social interaction is highly ranked by subjects, it may be important that 
both group leaders and other research staff be in regular contact with subjects whether or not 
they are regularly attending group. This may help get subjects back to group who may have 
been absent, but may also trigger improved adherence to wearing the physical activity 
trackers. 
 Future research should also be completed in a randomized study with a control group 
that can be used for comparison to the treatment group. The control group should be given a 
physical activity tracker that is the same as the treatment group, but should not be prompted 
to increase activity based on the exercise prescription. This would provide useful information 
to indicate which portion of the intervention is proving beneficial to the physical and mental  
health of individuals with SSDs.
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Screener’s name:________________                           Date:__________________ 
 
PACE-Life TELEPHONE SCREEN  
 
“Hi, I’m calling from the Physical Activity Can Enhance Life (PACE-Life) Study.  You had 
indicated an interest about the project and I’m following up to ask you some questions to 
help determine your eligibility for the study, and to answer any questions you may have 
about it. This should only take about 10-15 minutes. Please note that responding to these 
questions is voluntary and that all information will be kept strictly confidential. Once your 











“If you are still interested I’d like to get some general information first” 
 
Name:______________________________________ Age:______   DOB: _________
  
 
Gender:    M   F Ethnicity:___________ Occupation:_____________________           
  
Visit Transportation?  ___________     Location:___________________________   
 












hours	 all	 together.	 It	 will	 require	 48	 walking	 groups	 each	 lasting	 30	 minutes	 and	 4	
separate	assessments	lasting	2-3	hours	each.”	
	
“During	 the	 first	 visit,	 you	 will	 complete	 a	 variety	 of	 questionnaires,	 physical	 health	
measures	 (e.g.,	 weight,	 blood	 pressure,	 heart	 rate,	 waist/hip	 circumference)	 and	
complete	a	6	minute	walking	test.	During	the	second	and	third	visits,	we	will	repeat	the	







1. A short interview with a research assistant about your age, race, ethnicity, education, 
employment history, diagnosis, smoking history, and medications. 
2. Several paper-and-pencil questionnaires that involve answering questions about your 
physical health, exercise habits, motivation, and social support by rating your 
responses on a scale or circling your response. 
3. Walk for 6 minutes straight. 
4. Weigh yourself on a scale. 
5. Have your blood pressure, resting heart rate, and waist/hip circumference measured. 
6. Answering questions about your symptoms during a short interview with a research 
assistant.  
 




“Now I’m going to ask you some questions to determine your eligibility for the study. Do 
you agree to answer the following questions over the phone? If you are not eligible for the 
study, this information will be discarded. If you are eligible for the study, this information 
will be kept in a locked file with access granted only to research personnel.” 
 
(OBTAIN VERBAL CONSENT HERE): (YES/NO) 
 






schizophreniform	 disorder,	 or	 Unspecified	 Schizophrenia	 Spectrum	 or	 Other	
Psychotic	disorder?				YES					NO	
	





































Participants must answer Yes or No as bolded above. Any other response to these 
questions would exclude them from the study.  The only exception is if their answers to 
any of the PAR-Q questions would exclude them, we can get their permission to speak 
with their doctor to see if they can be medically cleared to participate.   
 
“DO YOU HAVE ANY QUESTIONS FOR ME ABOUT THIS STUDY?  I will get back 
to you within the next couple of days to let you know if you are eligible. My name and phone 




DAY/WORK PHONE:   LEAVE MESSAGE:  YES NO 
 
EVENING	PHONE:___________________	LEAVE	MESSAGE:	 	 YES	 NO	
	


































MEDICAL HISTORY AND PHYSICAL EXAM FORM 
 
   
PATIENT ID NUMBER         FORM CODE M H X   
	
	
VISIT     PATIENT INITIALS    VISIT DATE   /   / 2 0   
         M M  D D  Y Y Y Y 
	
 
Instructions This form is completed during the screening visit.  Evaluate each body system for past or active 
medical disorders.  Describe any pertinent findings.  
 
A.  MEDICAL HISTORY 
	
1) Cardiovascular disorders                                                         Yes            No       
a) Stroke ....................................................................................................  Y  N 
b) Transient Ischemic Attacks (TIAs) .........................................................  Y  N  
c) Coronary artery disease ........................................................................  Y  N 
d) Angina ....................................................................................................  Y   N 
e) Heart attack/ myocardial infarction ........................................................  Y   N 
f) Peripheral vascular disease ...................................................................  Y   N 
g) Abdominal aortic aneurysm ...................................................................  Y   N 
h) Congestive heart failure .........................................................................  Y   N 
i) Hypertension ..........................................................................................  Y   N 
j) Hyperlipidemia .......................................................................................  Y   N 
2) Diabetes ......................................................................................................  Y  
N→Go to Item 3      
   IF YES 
a) Is the patient now prescribed insulin? ...................................................  Y   N 




3) Endocrinological Disorders ..........................................................................  Y  N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
 
4) Neurological Disorders ................................................................................  Y  N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
5) Eyes .............................................................................................................  Y  N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
6) Ears, Nose or Throat ...................................................................................  Y  N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
 	 	 	 	  
7) Respiratory Disorders                                                        
 a)  Chronic Obstructive Pulmonary Disease ...............................................  Y  N 
    (If Yes, describe)  __________________________________    
                                ___________________________________  
b) Other pulmonary disease .......................................................................  Y  N 
(If Yes, describe)  ____________________________________  
                             ____________________________________  
8) Gastrointestinal ............................................................................................  Y  N 
(If Yes, describe)  ____________________________________  
                             ____________________________________  
9) Hepatic ........................................................................................................  Y  N 
(If Yes, describe)  ____________________________________  
                             ____________________________________  
 
10) Viral Hepatitis (A, B, C) ................................................................................  Y  N  
(If Yes, describe)  ____________________________________  
                             ____________________________________  
 




(If Yes, describe)  ____________________________________  
                             ____________________________________  
 
12) Dermatological .............................................................................................  Y   N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
15)   Musculoskeletal    
  a) Osteoarthritis .........................................................................................  Y  N 
(If Yes, describe)  ____________________________________  
                             ____________________________________  
b) Osteoporosis ...........................................................................................  Y  N 
(If Yes, describe)  ____________________________________  
                             ____________________________________  
16) Hematologic .................................................................................................  Y   N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
17) Immune System (include allergies) .............................................................  Y  N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
18)  Other Serious Infectious Diseases .............................................................  Y   N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
29)  Cancer ........................................................................................................  Y   N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
20)  Past Surgeries  ...........................................................................................  Y   N 
(If Yes, describe)  ____________________________________    
                             ____________________________________  
21)  Serious Injuries ...........................................................................................  Y   N 




                             ____________________________________  
 
B.  PHYSICAL EXAM 
Instructions:  Evaluate each body system for abnormal findings, and describe any findings.   
             Abnormal
 Normal 
22)  General Appearance/Skin ..........................................................................  A  
N 
(If Abnormal, describe)  ________________________________    
                                      ________________________________  
23)  HEENT .......................................................................................................  A  
N 
(If Abnormal, describe)  ________________________________    
                                      ________________________________  
24)  Cardiovascular ...........................................................................................  A  
N 
(If Abnormal, describe)  ________________________________    
                                      ________________________________  
25)  Chest ..........................................................................................................  A  
N 
(If Abnormal, describe)  ________________________________    
                                      ________________________________  
26)  Abdominal ..................................................................................................  A  
N 
(If Abnormal, describe)  ________________________________  
                                      ________________________________  
27)  Extremities/Joints .......................................................................................  A  
N 
(If Abnormal, describe)  ________________________________    
                                      ________________________________  
 
28)  Neurological ...............................................................................................  A  
N 
(If Abnormal, describe)  ________________________________  





29)  Other ..........................................................................................................  A  
N 
(If Abnormal, describe)  ________________________________  
                                      ________________________________  
 
















I have reviewed this patient’s medical history and performed a physical examination 
with pertinent positive and negative findings as documented on this form. Based on 
the examination, this patient is determined to be medically stable, consistent with 




















2. Gender	 	 	 	 	 	 	 	
	 ____	Male	 	 	 	 	 	 	
	 ____	Female	 	 	
	 	 	 	 	
3. Race	 	 	 	 	 	 	 	 	




	 ____	American	Indian	or	Alaskan	Native	 	 	 	 	 	
	 ____	Other	(specify)	________________________________	 	 	
	 	 	






































































Dose	 Frequency	 Indication	 Duration	
Prescribed	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	
	 	 	 	 	












1. Heart Rate and Blood Pressure: 
 
Have participant sit in quiet room with lights dimmed (or off) for 3-5 minutes before 
taking measurement. 
 
FIND PULSE AND COUNT FOR 1 MINUTE. 
 
Resting Heart Rate (from wrist): _____________    
** THIS MUST BE DONE BEFORE BLOOD PRESSURE USING PULSE FROM 
WRIST. 
 
Resting Heart Rate (from Fitbit): _____________ 
 
Put blood pressure cuff on participant and measure BP and HR. 
 
Resting Blood Pressure: _____________   Resting Heart Rate: _____________ 
 
 
2. Weight and Waist Circumference 
 
Remove all jackets, sweaters, and shoes for weight, height, and waist circumference 
 
Height (ft and in): _____________ 








Weight (lbs): _____________ 
 
 
Waist Circumference (cm): _____________ 
* Use the tape to circle the waist (sort of like a 
belt would) at the natural waistline, which is 
located above the belly button and below the rib 
cage. (If you bend to the side, the crease that 
forms is your natural waistline.) Don’t suck in 
your stomach, or you’ll get a false 
measurement. 
 
Hip Circumference (cm): _____________ 
*Start at one hip and wrap the tape measure around the rear, around the other hip, and back to 
where you started. Make sure the tape is over the largest part of the buttocks. 
 


















“The object of this test is to walk as far as possible for 6 minutes. You will 
walk back and forth in this hallway around the cones. You should pivot briskly 
around the cones and continue back the other way without hesitation. Now I’m 
going to show you. Please watch the way I turn without hesitation. 
[demonstrate by walking one lap yourself. Walk and pivot around a cone 
briskly] 	
“Cover as much ground as possible over 6 minutes. Walk continuously if 
possible, but do not be concerned if you need to slow down or stop to rest. 
The goal is to feel at the end of the test that more ground could not have been 
covered in the 6 minutes.  
“Please begin when you are ready. I will let you know how much longer you 
have after each minute.  When I say stop, please stop exactly where you are.” 
Once Participant begins walking: 
After 1 minute: “You are doing well. You have 5 minutes to go.” 
After 2 minutes: “Keep up the good work. You have 4 minutes to go.” 
After 3 minutes: “You are doing well. You are halfway done.” 
After 4 minutes: “Keep up the good work. You have only 2 minutes left.” 
After 5 minutes: “You are doing well. You have only 1 minute to go.” 
When the timer is 15 seconds from completion: “In a moment I’m going to tell you 
to stop. When I do, just stop right where you are and I will come to you.” 
When the timer rings (or buzzes), say this: “Stop!” Walk over to the patient. 
Consider taking the chair if they look exhausted. Mark the spot where they stopped 
by placing a piece of tape on the floor. 
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The Basic Psychological Needs in Exercise Scale 
 
Instructions. The following sentences refer to your overall experiences in exercise as opposed 
to any particular situation.  Using the 1-5 scale below, please indicate the extent to which you 
agree with the statements by circling one number for each statement. 
 I don’t agree 
at all 




I agree a lot I completely 
agree 
1. I feel I have made a 
lot of progress in 
relation to the goal I 











2. The way I exercise is 
in agreement with my 











3.  I feel I perform 
successfully the 
activities of my 
exercise program. 
1 2 3 4 5 
4. My relationships with 
the people I exercise 
with are very friendly. 
1 2 3 4 5 
5. I feel that the way I 
exercise is the way i 
want to. 
1 2 3 4 5 
6. I feel exercise is an 
activity which I do 
very well. 
1 2 3 4 5 
7. I feel I have excellent 
communication with 












8. I feel that the way that 
I exercise is a true 
expression of who I 
am. 
1 2 3 4 5 
9. I am able to meet the 












10. My relationships with 
the people I exercise 
with are close. 
1 2 3 4 5 
11. I feel that I have the 
opportunity to make 
choices with regards 



















WHY DO YOU ENGAGE IN EXERCISE? 
 
We are interested in the reasons underlying peoples’ decisions to engage, or not 
engage in physical exercise. Using the scale below, please indicate to what 
extent each of the following items is true for you. Please note that there are no 
right or wrong answers and no trick questions. We simply want to know how 
you personally feel about exercise. Your responses will be held in confidence 








Project FREE PACES 
Please rate how you feel at this moment about physical activity. Below is a list of feelings 
with respect to physical activity. For each feeling, please choose the number that best 
describes you. 
	

























































































































































































































































































































































































PACE-Life Subject Feedback Form 
This survey will be used to help make the program better. We appreciate 




Not at all true 1 2 3 4 5 Very true  
 
2. Overall, I enjoyed goal-setting/if-then plan sessions once a week. 
Not at all true 1 2 3 4 5 Very true 
 
3. I felt included in conversations during group. 
Not at all true 1 2 3 4 5 Very true 
 
4. I had a good relationship with the other members of the group. 
Not at all true 1 2 3 4 5 Very true 
  
5. I was motivated to attend groups because of the social interaction. 
Not at all true 1 2 3 4 5 Very true  
 
6. I had a good relationship with the walking group leaders. 







7. I felt motivated by group leaders during walking. 
Not at all true 1 2 3 4 5 Very true 
 
8. I was motivated to attend groups because of the health benefits I 
would gain from walking. 
Not at all true 1 2 3 4 5 Very true  
 
9. I enjoyed using a Fitbit to track my physical activity. 
Not at all true 1 2 3 4 5 Very true  
 
10. I found the Fitbit easy to use. 
Not at all true 1 2 3 4 5 Very true 
 
11. I am likely to continue to use my Fitbit after the study ends. 
Not at all true 1 2 3 4 5 Very true 
 
12. I enjoyed tracking my heart rate during walks. 
Not at all true 1 2 3 4 5 Very true 
 
13. I enjoyed receiving target heart rate goals throughout the 
study.  
Not at all true 1 2 3 4 5 Very true 
 
14. I felt the target heart rate goals were attainable for me.  







15. I enjoyed setting goals for home-based intensity walks.  
Not at all true 1 2 3 4 5 Very true 
 
16. I felt that my if-then plans helped me overcome barriers to 
walking. 
Not at all true 1 2 3 4 5 Very true 
 
17. Overall, I feel that my health has improved since joining 
PACE-Life.  
Not at all true 1 2 3 4 5 Very true 
 
18. If given the chance, I would join PACE-Life again.  
Not at all true 1 2 3 4 5 Very true 
 
Questions about Home-Based Walks 
19. I completed my home-based intensity walks at the following 












Questions about Attendance and Fitbit Use 
20. I missed group due to the following reasons (Circle all that 
apply): 
1. Issues with transportation  
2. Temperature being too hot outside 
3. Having to go to work or school at the same time as the 
groups 
4. Being too tired 
5. Not feeling like exercising 
6. Not feeling well physically  
7. Not feeling well emotionally 
8. Forgetting the day/time of the group  
9. Not getting along with other participants 
10. Not getting along with group leaders 
11. Having different group leaders during the study (i.e., 
not having same group leaders for entire study) 











22. Which were the 2 BIGGEST reasons you missed groups from those 
you listed above? 
 Reason 1: ________________________________	
Reason 2: ________________________________ 
23. I did not wear my Fitbit due to the following reasons (Circle 
all that apply): 
a. I forgot to put it on after charging it 
b. I forgot to put it on after taking it off to shower 
c. I forgot to put it on after taking it off to sleep 
d. I found it uncomfortable to wear 
e. It did not work well  
f. I did not like having my physical activity monitored 





24. Which were the 2 BIGGEST reasons you did not wear your Fitbit 
from those you listed above? 
 Reason 1: ________________________________	










Open Response Questions 
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